Page 1,334«..1020..1,3331,3341,3351,336..1,3401,350..»

No place for racism: an open letter from University of Auckland staff – The Spinoff

Posted: October 3, 2019 at 12:45 pm

Members of the university community on the re-emergence of white supremacist posters and stickers on campus, and the response from the vice-chancellor.

A university is a shared idea. We are not simply an institution with policies and processes, or an employer with employees. We are a community dedicated to the creation, preservation and sharing of knowledge. We build our collective understanding of the world and ourselves, while nurturing innovation and maintaining what is best in our society.

Given the nature of this place and any university worthy of the name no one person can truly speak on behalf of us all. However, the signatories of this letter declare that racism and white supremacy have no place at the University of Auckland.

Unfortunately, as has been covered in Craccum, The Spinoff and elsewhere, posters and stickers have recently appeared on campus drawing attention to the webpage of a group that aims to recruit young white men who will re-tak[e] control of [their] own country.

We have no difficulty in identifying this group and such displays as white supremacist in nature. Likewise, it is easy to state that the sentiments and ambitions it expresses are at odds with our nations foundation via Te Tiriti o Waitangi, however imperfectly observed: we never were a country for white men. Making this identification along with an understanding of where such sentiments can lead is part of the professional expertise of many scholars and students here at the University of Auckland. Finally, as human beings we clearly see that these sentiments are at odds with the norms of decent behaviour.

We understand the absolutist position that some take that freedom of speech extends to the right to speak in ways that are hateful. We also understand that the language of rights is complex and nuanced, recognising that such displays create an environment that brings harm to segments of our community, fraying the cultural tapestry that provides our diverse campus community with vitality and energy. We also note that by virtue of their race, gender, class, country of origin, religious affiliation, sexual or gender identity, many people empowered to judge conduct on university campuses are less likely to be the focus of hate speech, and may be slower to recognise its impact on its intended targets. However, speech has many forms, including gesture and nonviolent protest. If these posters constitute free speech, the same can be said of the actions of individuals who remove those that they encounter.

Finally, let us make this clear: these posters and the people who created them do not represent this university. As staff, students and alumni of the University of Auckland, we work to ensure that such sentiments do not take hold on campus. Our goal is to ensure that everyone who comes here flourishes within an environment that celebrates free and open enquiry, teaches the lessons of the past, and builds a better future for all.

Signed:

Richard Easther, Professor of Physics

Shaun Hendy, Professor of Physics

Peter Hunter, Distinguished Professor of Bioengineering

Brian Boyd, Distinguished Professor of English

Marston Conder, Distinguished Professor of Mathematics

Cather Simpson, Professor of Physics & Chemical Sciences

Jane Kelsey, Professor, Faculty of Law

Tom Bishop, Professor of English

Rosalind Archer, Professor of Engineering Science

Merryn Gott, Professor of Health Sciences, School of Nursing

Anthony Masamu Poole, Professor of Biological Science

James Sneyd, Professor of Mathematics

Juliet Gerrard, Professor of Biochemistry

Neil Broderick, Professor of Physics

Dr Tara McAllister, Te Pnaha Matatini

Greg Anson, Associate Professor, Exercise Sciences

Dame Anne Salmond, Distinguished Professor of Mori Studies and Anthropology

Rhys Jones, Senior Lecturer, Te Kupenga Hauora Mori

Julie (JR) Rowland, Associate Professor, School of Environment

Tracey McIntosh, Professor in Indigenous Studies

Sir Peter Gluckman, Distinguished University Professor, Liggins Institute

Kate Hannah, Te Pnaha Matatini

Siouxsie Wiles, Associate Professor, Molecular Medicine and Pathology

James Curran, Professor of Statistics

DrHeloise Stevance, Research Fellow in Physics

Frederique Vanholsbeeck, Associate Professor, Physics

Anoma Ratnayake, Faculty of Sciecne

JJ Eldridge, Senior Lecturer in Physics

Cate Macinnis-Ng, Associate Professor in Ecology

Suzanne Purdy, Professor of Psychology

Cushla McGoverin, Senior Research Fellow in Physics

Reza Amani, Research Fellow, Physics

Craig Stevens, Assoc ProfPhysics

Van Wijk, Kasper, Physics

Elizabeth Peterson, School of Psychology

Sarah Cowie, Senior Lecturer Psychology

Mark Harvey Senior Lecturer, Creative Arts and Industries

Elizabeth Peterson, Senior Lecturer School of Psychology

Duncan McGillivray Associate Professor of Chemistry

Giovanni Russello, Professor, School of Computer Science

Ian Lambie, Associate Professor of Psychology

David Krofcheck, Senior Lecturer in Physics Physics

Michael Davison, School of Psychology

Vivien Kirk Associate Professor of Mathematics

Liana Ball, School of Computer Science

Debbie Haefele, School of Computer Science

Chun Yan Lo, PhD student in Computer Science

Vivian Nayon, Accountant, Faculty of Science

Ankita Gangotra, PhD Student Physics

David Tse Jung Huang, Computer Science

Ulrich Speidel, Senior Lecturer in Computer Science

Gerald Weber, Senior Lecturer, Computer Science

Virginia Braun, Professor of Psychology

Tristan OHanlon, Professional Teaching Fellow, Physics

Mariam Almasri, Professional Staff

Kerry Gibson, Associate Professor in Psychology

Tanya Evans, Lecturer, Department of Mathematics

Thomas Lumley, Professor of Biostatistics

Kirsten Locke, Critical Studies in Education

Trudie McNaughton, Pro Vice-Chancellor, Equity

Clark Thomborson, Professor, School of Computer Science

Patricia Riddle, Senior Lecturer in Computer Science

Anthony Lambert, Professor of Psychology School of Psychology

Negar Zoka, Technical Staff, Physics

Fiona Jack, Senior Lecturer, Elam School of Fine Arts

Claire Postlethwaite, Associate Professor in Mathematics

Tanya Carter, Faculty of Science

Melinda Webber, Associate Professor, Te Puna Wnanga

Emma Willis, Senior Lecturer in Drama

Sibley Chris, Professor of Psychology

David Coppin, Research Fellow in Physics

Barry Hughes, Psychology

Nicolette Rattenbury, Professional Teaching Fellow, Mathematics

Nigel George, Director Psychology Clinic Science

Ben Mallett, Research Fellow Photon Factory

Reece Roberts, Research Fellow, School of Psychology

Sam Manuela, , Lecturer in Psychology Psychology

Douglas Elliffe, Professor of Psychology

Dr Steve Wells, Department of Physics

Tom Hinton, Research Fellow in Computer Science

Tia Reihana-Morunga, Dance Studies

Thegn Ladefoged, Professor of Archaeology Anthropology

Tariq Khan, Research Programmer

Jason Tutara, Kairahi, Te whare Putio

Matheson Russell, Senior Lecturer in Philosophy

Stuart McNaughton, Professor of Education and Social Work

Steven Dakin, Professor of Optometry & Vision Science

Katie Fitzpatrick, Associate Professor of Health & Physical Education, Curriculum and Pedagogy, Faculty of Education and Social Work

Claude Aguergaray, Senior Research Fellow, Physics

Thomas Lacombe, Research Fellow in Computer Science

Michelle Burstall, Senior Tutor, School of Psychology

Bryony James, Professor, Faculty of Engineering

More here:
No place for racism: an open letter from University of Auckland staff - The Spinoff

Posted in Molecular Medicine | Comments Off on No place for racism: an open letter from University of Auckland staff – The Spinoff

Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications – Science Advances

Posted: October 3, 2019 at 12:45 pm

INTRODUCTION

In 2015, the Obama administration launched the precision medicine initiative (1). An emerging engineering challenge within precision medicine is the need for versatile platform technologies that can be tailored to individual patients or pathologies (1, 2). A common approach within the fields of biomaterials and nanotechnology has been to design highly tailored formulations that target specific cell and tissue characteristics of a single pathology. These formulations, which can be fabricated in a variety of supramolecular structures [i.e., linear polymer conjugates (3), gels (4, 5), and self-assembled materials (6, 7)], recognize hallmark overexpressed cellular markers for the purpose of disease targeting. Nanoparticle carriers for precision medicine applications are typically dynamic in nature, swelling and/or degrading in intracellular environments to deliver therapeutic payloads to the cytosol of target cells (8).

In cancer treatment, there is precedence that multiple therapeutics can act synergistically to target and kill tumors. Chemotherapeutic agents act through a variety of mechanisms, including, but not limited to, DNA intercalation, enzyme inhibition, and cell cycle arrest (9, 10). Targeted agents, such as monoclonal antibodies, alter cell signaling pathways and engage the immune system. Photothermal therapy leads to tumor reduction by increasing membrane fluidity (~43C) or ablating the cells (~50C) (11). All of these therapeutic modalities benefit from targeting strategies, which concentrate the therapeutic agent within the tumor.

Each therapeutic option has distinct potential to aid in an individual patients treatment regimen. But, there is also marked variability between patients, necessitating precise and tailored treatments specific for the genetic and biophysical properties of the individual pathology. Advancements in genomic and proteomic technologies have made the collection of these relevant individual data a reality. The major hurdles left to overcome include, first, establishing predictive models of patients response to treatment and, second, engineering highly tunable platform technologies that deliver multiple therapeutic modalities in a patient-specific manner. Our modular strategy addresses the latter challenge and could serve as a useful tool in future studies on the former.

Previous studies on nanoparticle development for cancer precision medicine have focused on highly specified platforms that efficiently target and kill a single tumor population. For example, Conde et al. (12) recently designed a composite platform composed of gold nanorods, gold nanoparticles, therapeutic antibodies, and small interfering RNA encapsulated within an adhesive hydrogel patch. This system targeted and killed colorectal cancer cells through multiple modalities (i.e., photothermal therapy, RNA interference, and targeted chemotherapy), increasing treatment efficacy in vitro and in vivo.

In another illustrative example, Liu et al. (13) constructed a hierarchical nanomaterial assembly that delivered a cytotoxic protein (ribonuclease A) and antibiotic (doxycycline). This platform targeted cancer stem cells within heterogeneous cancer populations. The targeted, dual therapy led to a significant reduction in tumor volume relative to both the controls and individually administered therapeutics. These are only two examples, out of many promising studies on cancer nanomedicines that have used multiple therapeutic modalities (1215). There is a need, therefore, for a readily modifiable platform that facilitates the rapid customization of cancer nanomedicines to individual patients pathologies.

We previously demonstrated the ability to tune the hydrodynamic diameter and magnitude of pH response of poly(acrylamide-co-methacrylic acid) [P(AAm-co-MAA)] nanogels by modulating the monomer feed, polymerization parameters, or purification strategy (16). In the present work, our base platform is this random P(AAm-co-MAA) copolymer cross-linked into a nanogel with either a nondegradable or a redox-labile cross-linker. We present a new, modular sequence of nanogel modifications with small molecules, peptides, or proteins; these nanogels are multifunctional and multiresponsive, exhibiting dynamic loading and release of therapeutic payloads, engaging in a bioactive manner with biological substrates, transducing external signals into therapeutic heating, and promoting cellular internalization.

To achieve modular functionalization while retaining the bioactivity of conjugated molecules, we rely on facile and biocompatible conjugation schemes. While there are numerous bioconjugation strategies documented in the literature (1719), we use carbodiimide-mediated coupling to attach diverse ligands to pendant carboxylic acid groups via a stable amide bond. In this coupling scheme, carboxylic acid groups are activated with a catalyst to form a reactive ester intermediate, which is highly reactive with primary amines in slightly acidic aqueous solutions. We can, therefore, couple any water-soluble, amine-terminated moleculeincluding, but not limited to, proteins, peptides, and small moleculesdirectly to our polymer backbone. The diversity of bifunctional linker molecules that are available commercially, such as poly(ethylene glycol) derivatives (20, 21), further diversifies the ligands that our platform can accommodate, including those with amine, carboxylic acid, hydroxyl, or sulfhydryl groups.

We hypothesized that a single platform, when modified in a modular manner with bioactive components, could respond dynamically to tumor physiological environments, partition and elute therapeutic agents in a controlled manner, transduce external signals for therapeutic heating, and target tumor populations. We believe that this platformwhich can be modified to achieve environmental responsiveness, therapeutic delivery, and molecular recognitionis an enabling technology for delivering personalized and calibrated combination therapies. A summary schematic for our platform, along with the reagents, chemical modifications, and therapeutic modalities explored, is given in Fig. 1. In this proof-of-concept study, we demonstrate how a single, biocompatible platform can be quickly and precisely modified for personalized and precision medicine applications. Furthermore, in addition to standard characterization techniques, we developed and applied two new experimental methods: a quartz crystal microbalance with dissipation (QCM-D) assay for nanogel degradation and a high-throughput cell imaging assay for determining the kinetics of nanogel uptake. These new techniques expand upon the fields repertoire of experimental methods for evaluating and comparing new nanoparticle systems for precision medicine.

Nanoscale networks of acrylamide (AAm) and methacrylic acid (MAA), cross-linked with methylenebisacrylamide (BIS) or its degradable disulfide analog [N,N-bis(acryloyl)cystamine], were synthesized by inverse emulsion polymerization and modified via carbodiimide chemistry with tyramine (Tyr), N,N-dimethylethylenediamine (DMED), proteins, or peptides. In an additional post-synthesis step, gold nanoparticles (AuNP) were precipitated within DMED-modified (DMOD) nanogels. Here, we document the synthesis and modification of this nanogel platform and demonstrate the impact of nanogels modification on their ability to respond to the pH environment, load and release a model cationic drug, target cells, act as a functional enzyme, and transduce green light for photothermal therapy. Because of its tunability and the variety of therapeutic modalities enabled, we believe that this platform is suitable for precision medicine applications. DTT, dithiothreitol; TMB, 3,3,5,5-tetramethylbenzidine.

Our base platform for small moleculemodified nanogels was an ionomer collapsepurified P(AAm-co-MAA) nanogel, synthesized as described by Zhong et al. (16). These nanogels had a swollen hydrodynamic diameter of 768 nm, were 63% acidic copolymer by mass, and exhibited pH-responsive expansion/syneresis behavior with a critical pH transition point of 4.8. Ionomer collapsepurified nanogels, as opposed to those purified by dialysis alone, were selected because the basic conditions (0.5 N sodium hydroxide) are known to induce hydrolysis of some of the nanogel acrylamide content to acrylic acid, providing additional acid groups for bioconjugation. The increased presence of carboxylic acids allowed us to couple a greater quantity of functional small molecules to each nanogel.

An additional degree of tunability was introduced to the P(AAm-co-MAA) nanogels by introducing a biodegradable cross-linker. N,N-bis(acryloyl)cystamine is a bisacrylamide analog that contains a labile disulfide linkage. It has been used previously as a component of digestible gels for drug and gene delivery applications (2224). We successfully cross-linked P(AAm-co-MAA) nanogels with N,N-bis(acryloyl)cystamine. These biodegradable nanogels were similar in hydrodynamic diameter, zeta potential, and pH-responsiveness to their nondegradable analogs (fig. S1).

The kinetics and mechanisms of biodegradation for these nanogels were quantified by optical and gravimetric analyses. Optical analysis was conducted via dynamic light scattering (DLS) with a fixed detector position and signal attenuation. Under these measurement conditions, the count rate is related to the decrease in the number of suspended nanoparticles (25). Simultaneously, the hydrodynamic diameter measurements collected provide inference to the mechanism of biodegradation (i.e., surface erosion and bulk degradation). We assessed biodegradation by DLS for degradable nanogels in the presence of 10 mM dithiothreitol (DTT) or glutathione in 1 phosphate-buffered saline (PBS) at pH 7.4. DTT is a common reducing agent used for biological applications. It has been used previously to degrade systems cross-linked with N,N-bis(acryloyl)cystamine and was selected to ensure that the nanogels degrade completely. Glutathione (10 mM) in 1 PBS was selected as a biologically relevant reducing condition, as it mimics the intracellular environment (26).

The chemical mechanism of nanogel degradation by each reducing agent, as well as a pictorial depiction of the biodegradation process, is given in Fig. 2A. DLS analysis confirmed that both DTT and glutathione were able to reduce the disulfide cross-linker and consequently degrade the nanogel network (Fig. 2B). In the presence of DTT, the nanogels degraded rapidly and were indistinguishable from a linear polymer solution of the same concentration (i.e., completely degraded) after 40 min. Nanogels degraded with reduced kinetics in a 10 mM glutathione solution. The normalized count rate declined by 72.05.8% after 50 min in glutathione solution, and the nanogels were indistinguishable (by DLS count rate) from linear polymer after 48 hours.

(A) N,N-bis(acryloyl)cystamine cross-linked nanogels degrade via reduction of the disulfide. The diagram demonstrates how, after an initial period of surface erosion, the nanogels experience bulk degradation, leading to simultaneous network swelling. (B) DLS analysis of nanogel degradation. While bisacrylamide cross-linked nanogels did not degrade under reducing conditions, those cross-linked with a disulfide cross-linker were digested by both reducing agents (n = 4, mean SD). (C) QCM analysis demonstrated the kinetic decomposition of nanogels under reducing conditions and flow. While the mass of nondegradable nanogels was relatively unaffected by reducing conditions, the mass of degradable gels declined rapidly (n = 3, mean SD). (D) Hydrodynamic diameter analysis by DLS supported the degradation mechanism of initial surface erosion followed by bulk degradation. While the normalized count rate declined steadily throughout the extended measurement, the hydrodynamic diameter decreased initially (surface erosion) and then increased for the remainder of the experiment (i.e., decrease in cross-links led to a reduction in the total number of nanoparticles but swelling of the remaining intact nanogels) (n = 3, mean SD).

In QCM-D experiments, the nanogels were covalently conjugated to a gold-coated quartz sensor, and the mass loss, under reducing conditions, was monitored by measuring the change in the quartz sensors fifth harmonic resonance frequency (27). Mass loss was normalized to the initial mass of coupled nanogels to determine a relative measure. It is noteworthy that because the nanogels are covalently conjugated to the quartz sensor, the mass loss will never reach 100%. Some linear polymer strands will remain immobilized on the sensor following complete degradation of the cross-links.

Under a steady flow of fresh 10 mM DTT (1 PBS, pH 7.4), the mass of nondegradable nanogels increased slightly. This increase was likely due to adsorption of DTT molecules. On the other hand, the relative mass of degradable nanogels decreased rapidly, reaching a degraded state in 15 min (Fig. 2C). As shown in fig. S2, in parallel with an increasing resonance frequency, the dissipation of sensors coated with degrading increased. This indicated that as the nanogels were degrading, they were simultaneously losing mass and imbibing water. This observation was consistent with our DLS measurements, which showed that the nanogels simultaneously degraded and swelled under reducing conditions (Fig. 2D).

Next, we explored the ability to modify the pendant acid groups on P(AAm-co-MAA) with amine-terminated small molecules (tyramine and N,N-dimethylethylenediamine) to add phenol or tertiary amine groups to the polymer backbone, respectively. Nanogels modified to different extents with tyramine (TMOD) or N,N-dimethylethylenediamine (DMOD) were characterized by Fourier transform infrared (FTIR spectroscopy), potentiometric titration, DLS, and zeta potential measurement (Fig. 3).

(A) FTIR spectra of TMOD and DMOD nanogels, as compared with the unmodified formulation. The peaks at 1700 and 1200 cm1 correspond to the carboxylic acid, at 1660 and 1590 cm1 correspond to the amide, and at 800 cm1 correspond to the aromatic groups, confirming the incorporation of each small-molecule ligand through covalent coupling. FTIR analysis of all formulations is presented in fig. S1. (B) Nanogel modification proceeded with approximately 60% efficiency when the ligand concentration did not exceed the carboxylic acid concentration (stoichiometric ratios less than 1). (C) Potentiometric titrations were used to quantify the carboxylic acid content of all formulations, elucidating the extent of small-molecule coupling. (D) Modified nanogels exhibited a pH-responsive zeta potential transition (anionic to cationic), whereas unmodified nanogels were anionic across all pH values tested (n = 3, mean SD). (E) Unmodified and TMOD nanogels exhibited a pH-responsive collapse with a critical transition point at pH ~ 4.8. DMOD nanogels did not undergo substantial pH-responsive swelling.

FTIR analysis showed that the small molecules were covalently bound to the nanogel network, as evidenced by the reduction in peaks corresponding with the carboxyl carbonyl (1700 cm1) and carbon-oxygen single bond (1200 cm1). A graphical depiction of select formulations is given in Fig. 3A, with the full analysis of all formulations given in fig. S3. From the FTIR analysis, it initially appeared that the DMOD reaction proceeded with greater efficiency, as the disappearance of carboxylic acid peaks was more pronounced. However, potentiometric titration revealed that the percent of modified methacrylic acid moieties trended with the stoichiometric ratio of ligand to carboxylic acid similarly for both ligands (Fig. 3, B and C). Therefore, the trends observed in the FTIR spectra are likely reflective of the location of nanogel modification (surface for DMOD and bulk for TMOD) rather than the efficiency of the reaction. The circled formulations (0.5 TMOD and 0.78 DMOD) in Fig. 3B, which achieved a high degree of efficient molecular coupling, were used in each of the following experiments.

Potentiometric titration, pH-responsive zeta potential, and size measurements for TMOD, DMOD, and unmodified nanogels are also presented in Fig. 3 (C to E). As shown in the potentiometric titration analysis, unmodified nanogels were 63% polyacid [i.e., poly(acrylic acid) and poly(methacrylic acid)] by mass, as compared with 22 and 25% for the TMOD and DMOD nanogels, respectively. The reduction in acid content, because of modification, trended linearly with ligand concentration in the modification reaction at low extents of modification and plateaued at 69.83.7% modification. Full potentiometric titration analysis of all TMOD and DMOD formulations is presented in fig. S4.

All three formulations were anionic at pH values greater than five, as the carboxylic acid groups were predominantly deprotonated [pKa (where Ka is the acid dissociation constant), ~4.8] and held a negative charge. As the pH was reduced from 8 to 3, the TMOD and DMOD nanogels zeta potential was less negative than that of unmodified nanogels and became positive at pH 4.7. In this pH environment, as well as those more acidic, the carboxylic acid groups are protonated and therefore uncharged, whereas the tertiary amines contributed by N,N-dimethylethylenediamine and adsorbed sodium ions from the solution (5 mM sodium phosphate buffer) are positively charged. This pH-responsive ionization change for the modified nanogels is especially critical for environmentally responsive drug delivery, as will be shown in a later section.

The modified and unmodified nanogels hydrodynamic diameters, as measured by DLS, also changed in response to the pH environment. TMOD and unmodified nanogels exhibited similar pH-responsive collapses, with a critical pH transition of approximately 4.8. As the pH of the solution was dropped below 4, both the TMOD and DMOD nanogels aggregated. For the purpose of visualization, hydrodynamic diameter measurements from aggregated states were omitted from Fig. 3E. The full data are presented in fig. S5.

It is noteworthy that DMOD nanogels exhibited a nearly complete loss of pH-responsive swelling. This can be attributed to the fact that because of the modified networks amphoteric nature, it bears charge across all pH values. Its state of electrical neutrality at pH 4.7 is a result of balanced negatively and positively charged species, rather than a loss of ionization. On the contrary, the pH-responsive behavior of both the unmodified and TMOD nanogels suggests aggregation caused by a hydrophobic transition and loss of ionization. Taken in combination with the observed trends in zeta potential, this suggests that the TMOD nanogels negative-to-positive charge transition is a result of the association of ionic species, both salts from the buffer and additional tyramine molecules that were neither conjugated nor extracted during purification, rather than the network components themselves bearing a positive charge.

Suspensions of DMOD, TMOD, and unmodified nanogels were incubated separately with methylene blue in distilled water, and methylene blue loading was achieved through equilibrium partitioning. Methylene blue was selected as a model therapeutic agent because of its cationic nature, use as a photosensitizer, and similarity to the chemotherapeutic 5-fluorouracil. Methylene blue is a hydrophilic compound (logP=1.1), similar to 5-fluoruracil (logP=0.89). Methylene blueloaded nanogels were dialyzed against 1 PBS (of pH 4.5 or 7.4), which was exchanged regularly with fresh buffer to both simulate drug sequestration/metabolism and establish a semi-sink condition. The buffer condition (1 PBS at pH 7.4) was intended to simulate the pH environment in circulation, whereas the pH 4.5 condition was meant to emulate the environment of the late endosome, which nanocarriers will experience during lysosomal trafficking following cellular uptake. It is noteworthy that in the case of cancer drug delivery, the nanocarriers will experience a gradient of pH, decreasing from circulation through the endosomal pathway. The drug release environment was maintained at 37C, and methylene blue elution was monitored until complete release was achieved (28 hours).

Unmodified nanogels loaded significantly more methylene blue than their TMOD and DMOD derivatives (fig. S6). Prior to modifications, nanogels loaded methylene blue with 99.50.3% efficiency (equal mass ratio nanogels: methylene blue in ultrapure water). Increasing nanogel modification with tyramine or N,N-dimethylethylenediamine decreased the equilibrium partitioning of methylene blue. Specifically, TMOD and DMOD nanogels loaded methylene blue with 59.72.1% and 34.9 9.2% efficiency, respectively. This decrease in equilibrium partitioning, relative to unmodified control nanogels, is due to the hydrophobicity or cationic character that the respective ligands contribute. As a cationic and hydrophilic payload, methylene blue enages in complementary electrostatic interactions with deprotonated methacrylic acid groups. Furthermore, as methylene blue partitions preferentially in water over organic phases, we expected loading efficiency to correlate positively with nanogel hydrophilicity. In the preceding section, we showed that the extent of nanogel functionalization correlated with the amount tyramine or N,N-dimethylethylenediamine in the reaction solution. Furthermore, as each modification reaction depleted a pendant methacrylic acid group, there is a negative relationship between extent of nanogel modification and the available methacrylic acid groups to interact with methylene blue. Following modification with N,N-dimethylethylenediamine, the amphoteric nanogels lost pH-responsive swelling behavior. Their tertiary amine moieties, which are cationic, exerted a repulsive force on methylene blue. As a result of tyramine modification, the nanogels became more hydrophobic, similarly lowering the networks ability to partition methylene blue. These physicochemical characteristics of TMOD and DMOD nanogels are useful for responsive release behavior, but as they decrease the nanogelmethylene blue affinity, they decrease methylene blue loading efficiency.

A drug release experiment probed the ability of each modified or unmodified nanogel system to act as an intelligent drug delivery vehicle. In this experiment, nanogels loaded with methylene blue [nanogels (1 mg/ml), with corresponding loading described above] were placed in dialysis tubing [regenerated cellulose, molecular weight cutoff (MWCO), 12,000 to 14,000 kDa] and dialyzed against 1 PBS (pH 4.5 or 7.4). The dialysate was exchanged for fresh buffer every 2 hours to simulate drug metabolism. At each time point, a sample was taken from both within the dialysis tubing and outside it (i.e., the dialysate) to ensure precise measurement of the kinetic methylene blue release.

Unmodified nanogels exhibited sustained-release kinetics without a noticeable burst release or pH-responsiveness. In 2 hours, unmodified nanogels eluted 41.015.5% and 46.04.0% of their loaded methylene blue at pH 7.4 and 4.5, respectively (Fig. 4A). The unmodified nanogels consistency, in their rate of methylene blue elution between the two pH environments, is consistent with their continuously anionic zeta potential. While the pH 4.5 environment is below the unmodified nanogels pKa, sufficient acid moieties remained deprotonated to engage in electrostatic interactions with methylene blue and promote payload retention in a manner similar to the pH 7.4 condition.

(A) Methylene blue experienced complementary electrostatic interactions with unmodified nanogels at both pH 4.5 and 7.4, leading to sustained release in both conditions. (B) TMOD nanogels exhibited an initial burst release of methylene blue, where the quantity of that release was greater in acidic than neutral conditions. (C) DMOD nanogels exhibited a burst release of greater than 50% the loaded payload in each pH condition, with more rapid release in acidic than neutral conditions. (D) DMOD and TMOD nanogels exhibited similar methylene blue release behavior in acidic conditions, while unmodified gels exhibited a more sustained-release profile. (E) DMOD nanogels released methylene blue rapidly in 1 PBS (pH 7.4), while unmodified nanogels exhibited sustained-release and TMOD gels displayed intermediate behavior. The results in (D) and (E) indicated that the nanogels zeta potential is largely predictive for their release profile [all panels: n = 4, mean SD; *P < 0.05, **P < 0.01, and ***P < 0.001, two-way analysis of variance (ANOVA) with Tukey posttest].

On the other hand, TMOD nanogels exhibited an initial burst release, which varied significantly with the pH environment (78.59.6% and 43.7 18.9% of the loaded payload in the first 15 min, at pH 4.5 and 7.4, respectively; P < 0.05). After the burst release, TMOD nanogels gradually released methylene blue at pH 7.4 and rapidly released it at pH 4.5 (Fig. 4B). TMOD nanogels bear a cationic zeta potential in acidic buffers and further undergo a hydrophile-to-hydrophobe transition around the critical pH point (pH 4.8). These physical and chemical alterations, which were unique to the TMOD nanogels, explain their significant and unique pH-responsive methylene blue release profile. DMOD nanogels exhibited substantial burst release, followed by rapid methylene blue elution at both pH 4.5 and 7.4 (Fig. 4C). Methylene blue release was more rapid from DMOD nanogels at pH 4.5 than pH 7.4, which can be attributed to the transition from anionic to cationic zeta potential, as was shown previously.

Figure 4 (D and E) highlights the differences in pH-responsive methylene blue elution for the three formulations. All nanogel formulations eluted the entirety of the methylene blue payload within 28 hours. Unmodified nanogels exhibited a sustained-release profile in both pH conditions, demonstrating their use for controlled release but lack of responsive release. DMOD nanogels, conversely, released methylene blue rapidly in both pH environments, acting as neither a sustained-release depot nor a responsive delivery vehicle. TMOD nanogels acted as a pH-responsive delivery vehicle, responding to the acidic environment by rapidly releasing methylene blue. In the pH 4.5 environment, there were significant differences (P<0.001) between the relative elution of methylene blue from modified and unmodified nanogels. However, there were no differences between the methylene blue elution profiles of the DMOD and TMOD nanogels. This indicated that the release profile is driven primarily by the nanogels cationic zeta potential and not a hydrophile-to-hydrophobe transition (which was unique to TMOD). In the pH 7.4 environment, there were significant differences between the methylene blue elution profile of all three formulations.

These results illustrated how modification of the acid moiety, through changing the nanogels environmentally responsive swelling and ionization, altered the systems use as a drug delivery vehicle. While unmodified nanogels were most advantageous for steadily delivering a hydrophilic, cationic payload to the surrounding environment, TMOD nanogels exhibited rapid pH-responsive delivery. This pH responsiveness could lead to triggered release in the acidic tumor or endosome microenvironments. Therefore, the identity and extent of nanogel surface modifications should be carefully tuned to yield combinations of sustained and responsive release for specific drug delivery applications.

Our original design goal was to construct a tunable nanoscale hydrogel platform that was cytocompatible and could be diversified in a modular manner with bioactive moieties. To assess cytotoxicity, we incubated nanogels with murine fibroblasts for 24 hours and measured the impact of nanomaterial exposure on the cells membrane integrity and metabolic activity.

Intact nanogels (degradable and nondegradable) exhibited limited toxicity to fibroblasts after 24 hours of incubation, while nanogels degraded by 10 mM glutathione in cell culture medium were nontoxic at concentrations up to 2 mg/ml (fig. S7A). Fibroblast membrane integrity was largely unaffected by 24-hour incubation with nondegradable, degradable, or degraded nanoparticles (fig. S7B), indicating that the reduction in metabolic activity observed in fig. S7A was not due to cell lysis. Modification of nanogels with tyramine or N,N-dimethylethylenediamine did not alter their cytotoxicity (fig. S7C), as measured by cell metabolic activity following 24-hour exposure to a dose of 2 mg/ml. Peptide incorporation (fig. S7D) at approximately 2 weight % (wt %) of the dry nanogel weight did not significantly affect nanogel cytotoxicity (fibroblasts, 24-hour exposure, 2 mg/ml dose), as peptide-modified nanogels did not alter the cells metabolic activity.

We then monitored the extent to which nanogel toxicity differed across different cell types (fibroblast, macrophage, and colon epithelial). These were selected as model cell systems for the different cell types that would experience a nanomaterial insult following injection. We recognized that each cell line would interact with the nanogels differently, altering the extent to which the material impairs the cell viability. No significant differences were observed in the cells viability, as determined by metabolic activity or membrane integrity, for degradable, nondegradable, or degraded nanogels at concentrations up to 2 mg/ml (fig. S8). It is noteworthy that we saw a nonstatistically significant trend in macrophage activity, where metabolic activity increased and membrane integrity decreased at the top concentration (2 mg/ml, 24 hours). This does indicate acute toxicity to macrophages at this dose.

We assessed the impact of the nanogels chemistry, through surface modification, on their uptake by different model cell lines. We selected fibroblasts, macrophages, and epithelial cells because they model components of the connective tissue, immune system, and tissues/organs, respectively. Furthermore, by selecting colon epithelial carcinoma (SW-48) cells as the epithelial model, we simultaneously probed the impact of surface modification on preferential uptake by human tumor cells.

Modified nanogels for uptake studies were prepared in the same manner as in previous modification efficiency, therapeutic efficacy, and cytotoxicity studies, except for the addition of a carboxylic acidreactive fluorophore in the modification solution. To make the nanogels fluorescent, we added 5-(aminoacetamido)fluorescein at 0.8 wt % of the dry polymer (for comparison, the tyramine or N,N-dimethylethylenediamine ligand was added simultaneously at 10 wt %) to the modification solution. This fluorophore was conjugated to all of the nanogel formulations, including the unmodified nanogels.

The fluorophore was successfully conjugated to unmodified, TMOD, and DMOD nanogels, although a decreased fluorophore coupling efficiency was observed for DMOD nanogels. We produced calibration curves for all modified nanogel formulations and normalized our subsequent image analyses to the relative slope for each formulation (correction factors: unmodified, 1.27; TMOD, 1; and DMOD, 5.44). We also validated that fluorophore conjugation did not significantly alter the nanogels cytotoxicity by conducting MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and LDH (lactate dehydrogenase) assays for nanogel exposure to each of the three cell lines at concentrations up to 2 mg/ml. No significant cytotoxicity was observed by either measure at concentrations up to 1 mg/ml (24-hour exposure, all three cell lines) (fig. S9). Consequently, the maximum nanoparticle dose for all uptake studies was maintained at 1 mg/ml.

Even at low doses (less than 40 g/ml, 24-hour exposure), murine macrophages imbibed substantial quantities of all three nanogel formulations (Fig. 5, A to C). On the other hand, fibroblasts exhibited limited uptake of unmodified and TMOD but took up DMOD nanogels. Human colon epithelial cells took up all three formulations, exhibiting no preference for unmodified or TMOD nanogels, but a 13.4-fold increase in uptake when exposed to DMOD nanogels (relative to unmodified nanogels, 250 g/ml, 24-hour exposure). Representative images, visualizing nanogel uptake by each of the three cell lines, are given in fig. S10.

The relative uptake was computed by normalizing the green fluorescent protein (GFP) (nanoparticle) signal to the slope of the calibration curve and then normalizing that value to the 4,6-diamidino-2-phenylindole (DAPI) (cell nucleus) signal. Note that the y axis quantities differ between plots, as the DMOD nanogels were uptaken in significantly greater quantity than TMOD or unmodified nanogels. (A to C) Relative uptake of unmodified, TMOD, or DMOD fluorescent nanogels by each cell line, as a function of dose (24-hour exposure). (D to F) Kinetic uptake of unmodified, TMOD, and DMOD nanogels (400 g/ml dose). Representative images for each plot are given in fig. S10 (all panels, n = 4, mean SEM).

These dose-response results demonstrated that, while nanogel modification with N,N-dimethylethylenediamine generally increased uptake, the extent to which uptake was enhanced differed between cell lines. Compared with unmodified nanogels, DMOD nanogels exhibited a 4.5-fold increase in uptake by macrophages, 11.6-fold by fibroblasts, and 17.0-fold by colon carcinoma cells (250 g/ml, 24-hour exposure, all differences significant at the P < 0.05 level). This result suggests that the cell-nanomaterial interactions, which promoted uptake and were imparted by the N,N-dimethylethylenediamine moiety, triggered varying degrees of response from different cells. Furthermore, TMOD nanogels were uptaken similarly to unmodified nanogels. Tyramine modification led to a 21% decrease in uptake by macrophages, 31% decrease by fibroblasts, and 3.8% increase by colon carcinoma cells, none of which were statistically significant. This confirmed that a surface modification that imparts environmental responsiveness or alters therapeutic partitioning does not necessarily also enhance cell uptake.

Image analysis revealed that the nanogels interacted with each cell line in a different spatiotemporal manner. Nanogels did not interact substantially with fibroblasts, and when they did, they colocalized primarily with the cell membrane. Macrophages rapidly internalized the nanogels, with images demonstrating cytosolic colocalization in as little as 30 min. In the case of colon epithelial cells, nanogels first associated with the cell membrane, which preceded uptake. DMOD nanogels associated with the colon epithelial cells membranes and were internalized more rapidly than unmodified and TMOD nanogels (fig. S10).

Kinetic analyses of nanogel uptake further clarified the differences in nanogel uptake within cell lines and between formulations (Fig. 5, D to F). For precision medicine applications, we want to ensure that target cells (i.e., colon cancer cells) internalize the nanomaterial prior to complete therapeutic elution or clearance by off-target cells (i.e., fibroblasts or macrophages). It is relevant to recall that, depending on the particular surface modification and pH environment, the majority of the loaded methylene blue was eluted in less than 4 hours. Therefore, a formulation that rapidly associates with, and facilitates uptake by, target cells will enhance cytosolic delivery of the payload.

Murine macrophages took up all three nanogel formulations with near zero-order kinetics for the first 6hours. On the other hand, colon carcinoma cells exhibited a rapid cell-nanoparticle association [i.e., a spike in the green fluorescent protein (GFP)/4,6-diamidino-2-phenylindole (DAPI) signal in the first 15 min to 2hours], followed by a plateau in the signal intensity. Nanogels did not associate with the membrane or cytosol of murine fibroblasts until 24 hours of exposure. We looked specifically at nanogel uptake within the first 2 hours of dosing, as this is when majority of the methylene blue elution occurred in our drug release studies (at pH 7.4, 41% released by unmodified, 64% released by TMOD, and 91% released by DMOD). To compare the nanogel uptake at 2hours across cell lines, we computed the relative uptake as the ratio of the 2- and 24-hour uptake (400 g/ml dose). A two-way analysis of variance (ANOVA) revealed that formulation accounted for only 11.1% of the total variation in relative uptake (not significant), whereas the cell line identity explained 38.6% of the total variation in relative uptake (significant at the P < 0.001 level). Consistent with the dose-response study presented above, DMOD uptake by colon cancer cells was 12.4 times greater than that of unmodified nanogels. Tyramine modification did not significantly affect the extent of nanogel uptake by any cell line.

The rapid association and uptake of DMOD nanogels by colon cancer cells is particularly interesting, as it suggests that this particular surface modification could enhance specific drug delivery to target tumor cells. However, as these experiments were conducted in homogeneous, static cell cultures, we are unable to conclude whether this preference for colon tumor cells would translate to in vitro coculture or in vivo models.

One advantageous therapeutic quality of DMOD nanogels was their ability to act as an intrinsic reducing agent and, subsequently, act as centers for gold nanoparticle precipitation. DMOD nanogels with the three highest degrees of modification (0.78:1 DMOD or greater) were able to reduce gold chloride successfully, forming nanogel-coated gold nanoparticles. Nanogels with lesser quantities of N,N-dimethylethylenediamine did not form gold nanoparticles. Analysis of the composite nanogels absorbance spectrum (Fig. 6A) revealed that the conjugates absorb visible light strongly, with a maximum absorbance wavelength of 536 nm. In the transmission electron microscopy (TEM) images presented here (Fig. 6B), the gold nanoparticles are visible as dark circular regions within the nanogel bulk. Some, but not all, of the nanogels contained gold nanoparticles after the precipitation reaction.

Gold nanoparticles were precipitated in DMOD nanogels. DMOD gels with a 0.39:1 ratio of N,N-dimethylethylenediamine:methacrylic acid or less were unable to facilitate gold nanomaterial formation. (A) Absorbance spectra of composite nanogels containing gold nanoparticles. (B) Transmission electron micrographs of gold nanomaterials within 3.1:1 DMOD nanogels. Arrows point to gold nanoparticles. (C) Proof of concept for the composite nanogels ability to transduce visible light (=532 nm) into heat. DMOD (3.1:1) nanogels with gold nanoparticles effectively and rapidly heated a 1 PBS suspension. (D) Concentration-dependent photothermal activity of 3.1:1 DMODgold nanoparticle composites (n = 4, mean SD).

DMOD nanogelgold nanoparticle composites (3.1:1) were suspended at various concentrations in 1 PBS and were irradiated with a 532-nm laser at 200 mW. Within 30 s, the PBS suspension reached an equilibrium temperature (Fig. 6C), while the heat rapidly dissipated when the laser was turned off. Nanogels alone, in the absence of precipitated gold nanoparticles, did not heat the surrounding medium when irradiated with the same laser, indicating that the gold nanomaterials were acting as a transducing element. The heat generated by laser irradiation increased with nanoparticle concentration, with a maximum heating of 10.30.20C by a nanoparticle-in-nanogel suspension (1 mg/ml) (Fig. 6D).

Next, we demonstrated the feasibility of peptide and protein coupling to the base nanogel platform. Peptides can be used to impart specific biological behaviors, including molecular recognition, cell targeting, cell penetration, and endosomal escape. Bioactive proteins can contribute enzymatic activity to the otherwise inert network or be used as a molecular recognition unit for targeting applications.

Two independent peptide conjugation reactions were explored: one for coupling cysteine-containing peptides via a thiol-maleimide reaction and a second for coupling the N-terminal amine or pendant lysine groups to carboxylic acids in the nanogel network. Five diverse, cysteine-containing peptide sequences were selected to sample a diverse array of peptide properties (two cationic, two anionic, and one electrically neutral at physiological pH, all water soluble). These peptides were previously identified by the authors as candidates for trypsin recognition in physiological fluids. In the present study, they were used as model oligopeptides to optimize a generalized nanogel-peptide conjugation strategy and conclude relationships between a peptides formal charge and its coupling efficiency. In a two-step conjugation schema (Fig. 7A), we first coupled a maleimide-terminated linker molecule to the nanogels via carbodiimide-mediated coupling (pH 4.5). After 2 hours, we adjusted the nanogel suspension pH to 7.0 to favor the thiol-maleimide click reaction with the cysteine-containing peptides, as opposed to any aminecarboxylic acid side reaction (i.e., those between the nanogels carboxylic acid and the peptides N terminus, or peptide dimerization via the C and N termini of multiple peptides).

(A) A thiol-maleimide click reaction effectively conjugated cysteine-containing peptides to the nanogel network. (B) A carboxylic acidamine reaction linked the peptides N terminus with the carboxylic acidcontaining nanogels. (C) Differential incorporation of diverse peptides was explained by their net charge at physiological pH. (D) Nanogel conjugation at 2 wt % did not significantly alter the nanogel diameter or zeta potential. (E) Peptide content in the final conjugate product can be readily tuned by altering the peptide feed concentration via reaction scheme (B). (F) Horseradish peroxidase (HRP) and wheat germ agglutinin (WGA) were incorporated into nanogels with 56.4 and 81% efficiency, respectively. (G) HRP retained 66.533% of its activity upon conjugation to the nanogel platform, as evidenced by the ability of HRP-nanogel conjugates to convert TMB substrate. (H) WGA-NP conjugates retained native WGA activity, as they bound and stained the cell membrane of L929 murine fibroblasts (blue, DAPI stain of nucleus; red, WGA-NP conjugates) (C to F, n = 3, mean SD; G and H, n = 3, representative data).

We were successful in conjugating all five peptides to the network, demonstrating the feasibility of conjugating diverse peptide ligands to the platform. Peptide content, within each nanogel network, was quantified with a Micro BCA colorimetric assay. Cationic (FAHWWC and HAHWEC) and electrically neutral (CDHFAI) peptides were incorporated with nearly complete efficiency (theoretically complete incorporation was 2% of the dry weight). On the other hand, anionic peptides were incorporated with lesser efficiency (43.78.5% and 50.98.6% for CDNWQY and ADCFLQ, respectively) (Fig. 7C). This highlighted the effect of peptide formal charge, which influences its equilibrium partitioning in the nanogel phase during the conjugation reaction, on efficient coupling. The extent of nanogel decoration with anionic peptides was increased by elevating the concentration of the anionic peptide in the coupling reaction, but is still significantly less efficient than the coupling of neutral and cationic peptides. Nanogel decoration with peptide, at 2 wt %, did not significantly alter the nanogels size or zeta potential (Fig. 7D).

In a separate bioconjugation schema, the peptides were linked directly to the nanogel network via a reaction between the peptide N terminus and pendant carboxylic acid groups (Fig. 7B). Again, conjugation of a cationic peptide (HAHWEC) was efficient, as the quantity of the peptide within the network was readily controlled by modulating the peptide concentration in the coupling reaction (Fig. 7E). Our model anionic peptide (CDNWQY) was incorporated into the nanogels, but with a lesser efficiency (62.715.0%, depending on the peptide concentration in the modification solution).

Wheat germ agglutinin (WGA) and horseradish peroxidase (HRP) were conjugated to nanogels via carbodiimide-mediated coupling, with 2 wt % protein in the modification reaction. These model proteins were selected, as they are commonly applied for immunohistochemistry and biosensing applications, respectively. As a result of selecting these two protein targets, we had methods for verifying the retention of protein activity following conjugation to the nanogels. Furthermore, the result is applicable to other proteins that have affinity for extracellular targets (similar to WGA) or catalyze small-molecule conversion (similar to HRP). Each protein was incorporated successfully (Fig. 7F) and retained its bioactivity after conjugation. HRP activity was quantified by the colorimetric determination of enzymatic conversion of 3,3,5,5-tetramethylbenzidine (TMB) substrate. Standard curves were generated for TMB conversion as a function of HRP concentration (free HRP or HRP bound covalently to nanogels). By comparing the conjugated HRP activity to that of free HRP at the same concentration, we determined that 66.533% of the HRP activity was conserved (Fig. 7G). This provided evidence that our nanogels acted as scaffolds for retaining and presenting bioactive HRP to the surrounding environment.

WGA activity was assessed by determining the effectiveness with which WGA-labeled nanogels labeled fibroblast cell membranes. Fibroblasts were selected because unlabeled nanogels neither associate with fibroblast cell membranes nor are uptaken by fibroblasts within 2 hours, as quantified in Fig. 6 and illustrated in fig. S10. Therefore, colocalization of nanogels with the fibroblast membranes, or uptake into the cytosol, is due to the membrane-targeting activity of WGA. As shown in Fig. 7H, the WGA-labeled nanogels (red) colocalize with the cell cytosol, indicating that the conjugated WGA facilitated cell-nanogel interactions and subsequent uptake.

Here, we documented a modular, tunable nanogel platform for therapeutic applications. P(AAm-co-MAA) nanogels were decorated with numerous amine-containing ligands (i.e., small molecules, peptides, and proteins) and retained the ligand bioactivity (i.e., intrinsic reducing ability, pH sensitivity, hydrophobicity, molecular recognition characteristics, and enzymatic activity). We tuned the extent of ligand decoration by modulating the characteristics of the modification reaction and yielded a range of therapeutic capabilities, including cell targeting, enhanced nanomaterial uptake, intelligent drug delivery, and photothermal therapy.

In its present form, unmodified P(AAm-co-MAA) nanogels are suitable for loading high weight fractions of hydrophilic, cationic therapeutics. A suitable initial chemotherapeutic agent will be 5-fluorouracil, which is used to treat a number of cancers including colorectal cancer. These unmodified nanogels exhibited sustained therapeutic delivery for greater than 6 hours. Tyramine-modified nanogels were responsive to the pH environment and, as a result, delivered methylene blue more rapidly in acidic than neutral buffer. N,N-dimethylethylenediaminemodified nanogels were amphoteric in nature, eluted methylene blue the most rapidly of the tested formulations, and increased nanogel uptake by colon cancer cells.

Gold nanoparticle precipiation enabled photothermal therapy. Following DMOD nanogel accumulation in tumor sites, excitation with a focused green laser would heat the tumor tissue. Previous studies using gold nanoparticles for photothermal therapy applications have demonstrated efficacious heating using green light (28, 29). However, our platform combines photothermal therapy and chemotherapeutic delivery in a new, modular manner. In the future, platform functionalization with targeting peptides, monoclonal antibodies, or other targeting molecules could further enhance nanogel targeting and cell uptake.

As presented in Introduction, research on treating cancer with multiple therapeutic modalities is increasing in prevalence (30, 31). This platform technology, with its highly tunable nature, is amenable to delivering multiple chemotherapeutics and facilitating combination therapies, each with precise targeting or environmental responsiveness. Calibrated combinations of modified and unmodified nanogels in a single regimen could produce new physical distributions and release profiles of therapeutic agents in the future.

In addition to demonstrating the use of a new platform technology, we introduced multiple new characterization methods, which will be of utmost use to researchers developing nanoscale devices for precision medicine. In particular, while QCM methods have been used previously to study the deposition of nanomaterials on solid surfaces or the interfacial interactions governing monolayer self-assembly (3234), the use of QCM to study swelling and biodegradation of nanogel materials is novel. Similarly, while nanomaterial internalization by cells has been an active area of research, using methods such as confocal microscopy and flow cytometry (35, 36), we developed a high-throughput microplate assay for nanogel uptake. As a direct result of having this new analysis tool, we were able to screen the dose-dependent and kinetic uptake of our modified nanogels by three relevant cell lines.

In conclusion, we engineered a new nanogel platform, which is modularly tunable for precision medicine applications. We quantified the extent to which nanogel composition altered drug-material interactions for the loading and release of cargo, transduction of external signals, targeting of proteins, and uptake by cells. Our new methods, described herein, will also provide new tools to the drug delivery field to rapidly screen or precisely quantify biological interactions with engineered nanomaterials in the future.

Nanogels were synthesized by inverse emulsion polymerization, as previously optimized by Zhong et al. (16). Acrylamide [75 mole percent (mol %)], methacrylic acid (22.5 mol %), and methylene bisacrylamide (2.5 mol %) were dissolved in water at 42 wt %. This aqueous phase (2.762 ml) and N,N,N,N-tetramethylethylenediamine (50 l; catalyst) were added slowly to a stirring solution of Brij 30 (151.4 mM) and AOT (dioctyl sulfosuccinate sodium salt; 30.3 mM) in hexanes (50 ml) to form a water-in-oil emulsion. This prepolymer emulsion was purged with nitrogen for 20 min to remove dissolved oxygen, and polymerization was initiated by injecting 10 mg of nitrogen-purged ammonium persulfate [100 l of a freshly prepared stock (100 mg/ml) in ultrapure water]. After 2hours, the reaction was stopped by opening the round-bottom flask to air, and the nanogels were purified by precipitation in ethanol (three times) followed by either ionomer collapse or dialysis against a water:ethanol gradient.

In ionomer collapse, the nanogels were suspended in 0.5 N sodium hydroxide and precipitated with the addition of a threefold volume excess of acetone. Precipitated nanogels were collected by centrifugation (3200g for 5 min), and the collapse procedure was repeated an additional four times. In gradient dialysis, nanogels were suspended in a 50:50 water:ethanol mixture and dialyzed against a decreasing water:ethanol gradient for >5 days with twice-daily dialysate change. Nanogels purified by both ionomer collapse and gradient dialysis were then exchanged into ultrapure water by dialysis. All purified nanogels were lyophilized and stored at room temperature.

For studies involving degradable nanogels, synthesis was conducted in the manner described above, with N,N-bis(acryloyl)cystamine substituted for methylene bisacrylamide. N,N-bis(acryloyl)cystamine is a biodegradable cross-linker that is labile via reduction of its disulfide bond. Cross-linker comprised 2.5 mol % of the monomer feed, and the masses of acrylamide and methacrylic acid were adjusted such that total monomer concentration remained 42wt % in water.

Nanogels were suspended at 10 mg/ml in 1 PBS and adjusted to pH 7.4. Then, 0.5 ml of nanogels and 0.5 ml of DTT or glutathione (20 mM in 1 PBS, pH 7.4) were mixed in a polystyrene cuvette, immediately after which light scattering measurements were recorded. Measurements were recorded using a Zetasizer Nano ZS (Malvern) with a manual attenuation (Attn, 7), measurement position (4.65 mm), and measurement time (10s). Measurements were taken repeatedly for 50 min. In each interval, a hydrodynamic diameter and count rate were recorded. Because count rate trends with the number of particles in solution (37), the count rate at a given time, normalized to the initial count rate, provided a measure of the degree of degradation.

QCM studies were conducted using QSense E4 QCM-D (Biolin Scientific). Uncoated gold sensors were washed in a 5:1:1 volume ratio of ultrapure water, ammonia hydroxide (25 volume %), and hydrogen peroxide (30 volume %) at 75C for 5 min. The sensors were then washed with an excess of water and an excess of ethanol and were dried under nitrogen. Immediately prior to experimentation, clean sensors were treated with ultraviolet/ozone for 10 min.

All experiments were conducted in their entirety at 37C and a flow rate of 0.200 ml/min. A stable baseline for the sensors was achieved by flowing 1 PBS for at least 10 min. Then, the sensors were coated with an amine-terminated monolayer through the addition of cysteamine HCl (10 mg/ml in 1 PBS). Nanogels activated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (twofold molar excess relative to MAA) were flowed over the modified sensor at 2 mg/ml. After a stable coating was obtained (as evidenced by no further fluctuation in the frequency or dissipation), 1 PBS was flowed over the sensor to wash away unreacted polymer and remaining catalyst. The change in resonance frequency, as a result of nanogel coupling, was recorded as a measure of the bound nanogel mass.

Nanogels were swelled in a series of buffers differing in ionic strength (PBS buffers at pH 7.4 diluted to 5, 2, 1, 0.5, 0.1, and 0.01 with ultrapure water) as well as 1 PBS buffer adjusted to different pH values (3, 5, 7, 9, and 11). The purpose of these swelling steps was twofold: to quantify the responsiveness of nanogels to environmental conditions and to verify that the nanogels are behaving as expected despite their immobilization. The frequency and dissipation values were monitored to quantify the nanogels water uptake or expulsion in each buffer condition, as well as to determine the viscoelastic properties of the nanogel layer.

Nanogels were degraded by flowing a 10 mM DTT solution over the nanogel-modified sensors. The frequency and dissipation values were monitored to determine the mass loss during degradation as well as probe changes in viscoelastic properties that indicate the degradation mechanism (i.e., bulk degradation or surface erosion). In each case, the mass immobilized or adsorbed was quantified by the Sauerbrey equationm=Cfnwhere m is the mass adsorbed or immobilized, C is a constant that depends on the intrinsic properties of quartz [for a 5-MHz crystal, C = 17.7 ng/(cm2 Hz)], and n is the overtone number (i.e., 3 and 5). The relative mass was computed by normalizing the change in mass, due to swelling or degradation, to the mass of nanoparticles immobilized (32, 38). It is also equal to the ratio of the frequency changesmdegradationmimmobilized=fdegradationfimmobilized

Purified, dried nanogels were suspended in 10 mM MES buffer and adjusted to pH 4.50.05. Tyramine or N,N-dimethylethylenediamine was dissolved in water at 25 mg/ml. EDC hydrochloride was dissolved immediately prior to use in MES buffer at 56 mg/ml. Each reaction was composed of 5 ml of nanogels (50 mg), 1 ml of EDC solution (56 mg of EDC, a 2:1 molar ratio EDC:MAA by original synthesis feed, and 0.8:1 molar ratio EDC:acid subunit when confirmed by titration analysis), and a variable volume of tyramine or N,N-dimethylethylenediamine (1.6 ml for the highest degree of modification and cut by half for each subsequent reaction). The highest modification ratio (by moles) tested was 2:1 tyramine:MAA and a 3.1:1 N,N-dimethylethylenediamine:MAA. In each highest modification case, the ligand concentration was 80% that of the nanogels by mass. As a control, nanogels were subjected to the reaction conditions (MES buffer, pH 4.5, 56 mg of EDC) in the absence of ligand. Modified nanogels were purified by dialysis against ultrapure water (>72 hours, frequent water changes). Reactions were completed in duplicate.

The physicochemical properties of nanogels were quantified by attenuated total reflectanceFTIR spectroscopy (Nicolet iS10 FTIR Spectrometer; Thermo Fisher Scientific), DLS, and zeta potential measurement (Zetasizer Nano ZS; Malvern). Dried nanogels were pressed in contact with a germanium crystal, and the IR absorption spectrum was recorded from 4000 to 675 cm1. All presented spectra are the average of 64 measurements. All spectra were normalized such that the magnitude of their largest peak was 1U, and their baseline was set at zero. All DLS measurements, unless otherwise stated, were obtained at a nanogel concentration of 2 mg/ml in 1 PBS, adjusted to pH 7.4. All zeta potential measurements, unless otherwise stated, were taken at a nanogel concentration of 2 mg/ml in 5 mM sodium phosphate buffer, adjusted to pH 7.4.

The extent of modification with tyramine, N,N-dimethylethylenediamine, or 5-(aminoacetamido)fluorescein was quantified by potentiometric titration. Ten milligrams of modified or unmodified nanogels was suspended in 60 ml of 5 mM potassium chloride buffer. The suspension was adjusted to pH 10 with 1 N sodium hydroxide to completely deprotonate pendant methacrylic acid groups. The solution was titrated through the equivalence point with 0.01 N hydrochloric acid (HCl) using an autotitrator (Hanna HI901C). We titrated the nanogel suspensions from a basic-to-acidic environment to ensure that the nanogels were swollen during the entirety of adjustment to equivalence. The equivalence point for methacrylic acidcontaining nanogels was consistently at pH 4.8.

We assume that at equivalence (pH 4.8), exactly half of the acid moieties are protonated. We also assume that at a pH three points above equivalence (pH 7.8), 0.1% of the acid groups are protonated. The volume of 0.01 N HCl needed to adjust pure 5 mM KCl buffer from pH 7.8 to pH 4.8, as well as the volume needed to adjust each nanogel suspension the same increment, was recorded. Using these measurements and the stated assumptions, we calculated the mass fraction of methacrylic acid groups usingmMAAmnanogels=(10.499)(VsuspensionVbuffer)NtitrantMWMAA1mnanogelswhere mnanogels was 0.010 g, Ntitrant was 0.01 M, the molecular weight of methacrylic acid (MWMAA) is 86.06 g/mol, and both volumes were measured in liters.

The extent of nanogel functionalization with peptides or proteins was quantified using a Micro BCA colorimetric assay (Thermo Fisher Scientific), as described previously (39). Modified or unmodified nanogels, suspended at 2 mg/ml in 1 PBS (pH 7.40.05), were combined at an equal volume ratio with Micro BCA working reagent and mixed for 2 hours at 37C (constant mixing). The absorbance of the reduced supernatant (=562 nm) was used to quantify the suspensions peptide concentration, relative to standard curves generated for each pure peptide or protein. The background absorbance of unmodified nanogels under the same testing conditions was subtracted from each measurement.

L929 murine fibroblasts, RAW 264.7 murine macrophages, and SW-48 human colorectal epithelial carcinoma cells were chosen as model cells to properly assess nanomaterial interactions with model connective, immune, and epithelial tissues that would interact in vivo. All cells were cultured in T-75 tissue culturetreated flasks and were used at passages ranging from 6 to 20.

Cells were incubated in a sterile 37C, 5% CO2 environment. Culture medium for all three cell lines was phenol redcontaining high-glucose Dulbeccos modified Eagles medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 2 mM l-glutamine, and 1% penicillin-streptomycin. Cells were passaged once they reached 80 to 90% confluency. Experiment medium for all three cell lines was phenol redfree, high-glucose DMEM with 2% FBS, 2 mM l-glutamine, and 1% penicillin-streptomycin. Experiments were conducted when cells reached 50 to 70% confluency.

For all cell assays, L929 and RAW 264.7 cells were seeded in tissue culturetreated 96-well plates at a density of 10,000 cells per well. SW-48 cells were seeded in similar plates at 25,000 cells per well. Cells were given a minimum of 24 hours to attach and reach 50 to 70% confluency before cytotoxicity, or nanogel uptake assays were performed.

Methylene blue was selected as a model hydrophilic, cationic therapeutic. Methylene blue is a photosensitizer and was selected because of its similarity in hydrophilicity and ionization to hydrophilic chemotherapeutics (i.e., 5-fluorouracil), as well as its compatibility with our hydrophilic, anionic nanogels. Methylene blue was loaded into modified and/or unmodified nanogels by equilibrium partitioning in ultrapure water. For loading experiments, methylene blue (2 mg/ml) and purified nanogels (2 mg/ml) were mixed for 15 min in distilled water. Drug loading was quantified by removing a sample (500 l) and separating the unbound drug by ultrafiltration (Sartorius Vivaspin 500; 300,000 MWCO). The unbound methylene blue was quantified by absorbance (=590 nm) relative to a standard curve. Loaded or partitioned methylene blue was quantified usingQ=(C0Ce)Vmwhere Q is the mass ratio of loaded methylene blue to nanogels, C0 is the methylene blue concentration in the loading solution (1 mg/ml), Ce is the unbound concentration of methylene blue (that passed through the filter), V is the volume of the loading solution, and m is the mass of nanogels in the loading solution.

Prior to drug release experiments, unloaded drug was removed by dialysis against ultrapure water (24 hours, 12,000 to 14,000 MWCO). Methylene blueloaded nanogels [10 ml, nanogels (1 mg/ml), methylene blue (1 mg/ml) in the loading solution, variable methylene blue loaded], still within dialysis tubing, were transferred to 1 PBS solution (400 ml) at pH 4.5 or 7.4 under constant stirring at T=37C. At regular time intervals (15 min, 30 min, 1 hour, 1.5 hours, 2 hours, 4 hours, 8 hours, 24 hours, and 28 hours), samples were taken both from within and outside the dialysis tubing. For samples drawn from within the dialysis tubing, loaded and released methylene blue were separated by ultrafiltration. The dialysate was exchanged for fresh buffer at the 2-hour time point and each time point thereafter to simulate drug metabolism. This dialysate exchange ensured that a concentration gradient (between the nanogel and solution phases) was maintained to facilitate complete methylene blue elution. The total released drug was quantified for the first time point asmreleased=Vwithin tubingCMB,within tubing+VdialysateCMB,dialysatewhere the volume parameters describe the total volume within and outside of the dialysis tubing, respectively, and the concentration parameters capture the released methylene blue present in each solution location.

Note that the volume within the dialysis tubing changes with each time point (as sample is depleted) and that released methylene blue within the dialysis tubing eventually dissipates into the dialysate. It is important to correct for these mathematically. For example, at the 30-min time point, the methylene blue released in the 15-min increment from 15 to 30 min was calculated usingmreleased=(Vwithin tubingCMB,within tubing)t=30(Vwithin tubingCMB,within tubing)t=15+(VdialysateCMB,dialysate)t=30(VdialysateCMB,dialysate)t=15

Please note that this equation holds for all future time points as well, changing the respective time indicators, with the one exception that the final term is omitted if the dialysate buffer was exchanged prior to the interval.

Culture medium was removed by plate inversion and replaced with experiment medium containing hydrogel microparticles (0.0005 to 2 mg/ml). In the case of degraded nanogels, the culture medium containing degradable nanogels was spiked with 10 mM glutathione and incubated at 37C for 24 hours prior to the experiment.

Plate layouts were pseudorandomized. To pseudorandomize, we distributed the samples and controls throughout each microplate to ensure that each sample/control was positioned equitably along the plate exterior or within the interior. This controlled for variation in cell proliferation explained by well location within the plate. Following 24-hour incubation, cytotoxicity was quantified via metabolic activity (MTS) and cell membrane integrity (LDH assay).

For MTS assays, the nanogel-containing experiment medium was removed by plate inversion, and cells were washed with 37C Dulbeccos PBS (DPBS) twice to remove adsorbed nanogels and cell debris. Then, 100 l of MTS assay buffer (MTS diluted 1:6 in experiment medium) was added to each well, and relative metabolic activity of each cell sample was quantified by measuring the MTS metabolism (90 min at 37C) within each well, relative to control, as specified by the manufacturer (Promega).

For LDH assays, LDH assay buffer (100 l) was added directly to the cell media containing nanogels and any cell debris. The relative membrane integrity was calculated by measuring the LDH activity (excitation, 560 nm; emission, 590 nm) according to the following relationRelative membrane integrity=100100sampleblankmax releaseblankwhere the sample measurement is the fluorescence of the treatment media with LDH assay buffer, the blank is the cell culture medium and assay buffer without cells, and the max release is the LDH buffer and treatment media after a 20 min incubation of cells with media and 2 l of lysis buffer (Promega).

A high-throughput fluorescence imaging assay was developed for rapidly screening cells uptake of modified and unmodified nanogels. Fluorescently tagged nanogels, with the addition or lack of tyramine or N,N-dimethylethylenediamine, were suspended in phenol redfree DMEM at concentrations ranging from 1000 to 6.25 g/ml. Cells were dosed with either a gradient of nanogel concentration (24-hour incubation) or a set concentration for a range of time (concentration of 400 g/ml).

For concentration-dependent nanogel uptake assays, culture medium was removed from each well by plate inversion and replaced by treatment medium containing suspended nanogels. Cells were allowed to incubate for 24 hours in the presence of nanogels (100 l per well). Following incubation, the nanogels were removed by aspiration, followed by three washes with cold DPBS. Cells were fixed with cold paraformaldehyde solution for 10 min (50 l per well).

For time-dependent nanogel uptake assays, culture medium was removed from each well and replaced with treatment media containing nanogels (400 g/ml) by aspiration in an inverse time manner (i.e., 24-hour time point first, 15-min time point last) (100 l per well). This was scheduled in such a way that all wells reached their end point simultaneously. Nanogel suspensions were removed from the cells by aspiration, and the cells were washed three times with cold DPBS (100 l per well). These cells were also fixed with cold paraformaldehyde solution (50 l per well).

Cells were stained directly in the microplates for fluorescence imaging. Following fixation, each well was washed three times with cold Hanks balanced salt solution (HBSS) (100 l per well). Then, the cell membranes were stained with a WGA Alexa Fluor 594 conjugate solution (3 g/ml) in cold HBSS (15 min) (50 l per well). After three more washes with cold HBSS (100 l per well), the cells were stained with a DAPI solution (1 g/ml) in cold HBSS for 10 min (50 l per well). Each well was washed three times with cold HBSS prior to imaging (100 l per well). Imaging was conducted with 100 l of fresh HBSS in each well.

Cell imaging was conducted at high throughput using a Cytation 3 plate reader (BioTek) with Gen5 software (version 3.04) equipped with DAPI, GFP, and Texas Red filters (DAPI: excitation, 377 nm; emission, 447 nm; Texas Red: excitation, 586 nm; emission, 647 nm; and GFP: excitation, 469 nm; emission, 525 nm) and an Olympus 20 objective. Imaging parameters were optimized to the most fluorescent samples to prevent saturation and were held constant to enable both qualitative and quantitative image analyses between cell lines and treatments [DAPI: light-emitting diode (LED) intensity, 5; integration time, 63; and gain, 0; Texas Red: LED intensity, 10; integration time, 100; and gain, 13.8; and GFP: LED intensity, 10; integration time, 158; and gain, 15]. Four images were taken for each well, and images were preprocessed with a background subtraction step prior to qualitative analysis.

For quantitative analysis, the fluorescence of the whole well was taken for each relevant channel (DAPI, Texas Red, and GFP with gain values of 60, 100, and 120, respectively). To normalize the nanoparticle signal intensity to the cell count, we normalized the fluorescence intensity of GFP to the DAPI channel. The relative nanogel uptake for each cell linecondition pair is given as this ratio.

To precipitate gold nanoparticles within the hydrogel nanogels, chloroauric acid (0.05 wt %) and nanogels (1 mg/ml) were suspended in ultrapure water and mixed (Eppendorf ThermoMixer) at 1000 rpm and 60C for 1 hour. Nanogels with precipitated nanoparticles were used in further experiments without purification. These composite nanogels were characterized by their visible absorption spectra (300 to 1000 nm in 1-nm intervals using a Cytation 3 microplate reader) as well as by TEM (FEI Tecnai Transmission Electron Microscope, operating at 80 kV, cast on carbon-coated grid, and stained with uranyl acetate).

Photothermal experiments were conducted as previously described (40, 41). For photothermal therapy experiments, a 532-nm laser diode (PN156-10.07-0447) was used. This laser wavelength was within the maximum absorbance peak of the gold nanoparticlecontaining nanogels. The nanogels were suspended in ultrapure water at 1 mg/ml, and 1 ml of each nanogel suspension was added to a 24-well microplate. The laser, operated at a power of 200 mW, was focused on a circular area with a 6-mm diameter using a convex lens (Thorlabs Inc.), which was mounted at a 30 angle. Dynamic fluctuation in temperature, within the circular area, was measured using an indium antimonide IR camera (FLIR Systems Inc.).

For peptide modification through a thiol-maleimide click reaction, the nanogels were first modified with N-(2-aminoethyl)maleimide. Purified, dried nanogels were suspended in 10 mM MES at 10 mg/ml and adjusted to pH 4.5. Carboxylic acids were first activated by the addition of a twofold molar excess EDC (relative to MAA content), after which the N-(2-aminoethyl)maleimide trifluoroacetate salt was added. The amount of this linker molecule added was calculated such that if 100% peptide coupling were achieved, then the final peptide concentration would be 2 wt % of the dry nanogel. During this modification reaction, the pH was carefully maintained at 4.5. After 30 min, the pH of the solution was raised to 7.0 with 1 N sodium hydroxide (to terminate the carboxylic acidamine reaction), and the thiol-containing hexamer peptides (FAHWWC, HAHWEC, CDNWQY, ADCFLQ, and CDHFAI) were dissolved in 0.1 PBS at 10 mg/ml, adjusted to pH 7, and added (final peptide concentration of 2 wt % relative to the nanogels). This thiol-maleimide reaction was allowed to proceed overnight at room temperature under constant mixing. The nanogels were purified by dialysis against ultrapure water (12,000 to 14,000 MWCO, >72 hours, frequent water changes).

For peptide modification through a carboxylic acidamine reaction, the nanogels were suspended in 10 mM MES, and pH was adjusted to 5.5. Carboxylic acids were activated with a twofold molar excess (relative to MAA) of EDC. Peptides were dissolved in 10 mM MES at 10 mg/ml and adjusted to pH 5.5. The proper volume of the peptide solution was added to each modification reaction to achieve the desired extent of peptide decoration (i.e., 0 to 10 wt %, relative to the dried nanogels). Nanogels were purified by dialysis against ultrapure water.

Nanogel modification with bioactive proteins was conducted in the same manner as the peptide carboxylic acidamine coupling, except for that WGA Alexa Fluor 594 (Thermo Fisher Scientific) or HRP (Worthington) was dissolved at 1 mg/ml in 10 mM MES and added to the modification reaction at a final protein concentration of 2 wt % (relative to the dried nanogels).

HRP bioactivity within modified nanogels was quantified by its ability to convert TMB substrate, relative to free HRP. Nanogels were dissolved at 2 mg/ml in 1 PBS (pH 7.4 0.05) and diluted 1:8000 for a final concentration of 0.25 g/ml. Lyophilized HRP (Worthington) was also dissolved at 2 mg/ml in 1 PBS and diluted 1:1,000,000 for a final concentration of 0.002 g/ml. A calibration curve for HRP activity was generated via serial dilution with a maximum concentration of 0.002 g/ml. In a 96-well microplate, 100 l of HRP solution or nanogel suspension was mixed with 100 l of TMB substrate solution (Pierce). After 10 min of incubation at ambient conditions, the reaction was stopped by adding 50 l of 1 N sulfuric acid. The reaction product was quantified by visible absorbance at =450 nm.

WGA bioactivity was quantified by its ability to recognize fibroblast cell membrane (via interaction with sialic acid and N-acetylglucosaminyl residues in the membrane). Fibroblasts were seeded in 96-well microplates at 10,000 cells per well and allowed to attach overnight. Cells were incubated in phenol red-free DMEM, supplemented with 2% FBS, containing WGA-conjugated nanogels at 1 mg/ml for 2 hours. As control samples, separate wells were incubated in media alone or media with unmodified nanogels (1 mg/ml) (2 hours). All wells were washed three times with cold DPBS and fixed with cold paraformaldehyde (IC Fixation Buffer; Invitrogen) for 10 min (50 l per well).

After fixation, the nuclei of all cells were stained with DAPI (1 g/ml in cold HBSS, 10 min). The plasma membranes of positive control cells were stained with WGAAlexa Fluor 594 (3 g/ml in cold HBSS, 15 min). After each staining step, all wells were washed three times with cold HBSS (100 l per well).

Fibroblasts were imaged using the fluorescence imaging capabilities of the Cytation 3 microplate reader, equipped with a 20 Olympus objective. So that images could be compared qualitatively, common imaging parameters were used for all images [DAPI (nucleus): LED intensity, 5; integration time, 50; and gain, 0; Texas Red (WGA-nanogels and membrane stain): LED intensity, 10; integration time, 130; gain, 13.6]. Images were processed using Gen5 software (version 3.04), where the background fluorescence was subtracted from each image.

Original post:
Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications - Science Advances

Posted in Molecular Medicine | Comments Off on Synthetic networks with tunable responsiveness, biodegradation, and molecular recognition for precision medicine applications – Science Advances

The world’s first psilocybin research center is opening in Jamaica – Big Think

Posted: October 3, 2019 at 12:45 pm

When I noticed articles floating around about the opening of the world's first psilocybin research center, I figured they were from satire websites. Sure, the case for therapeutic psychedelics is growing: ketamine is the first psychedelic to be legally prescribed for depression in America; MAPS is entering phase 3 trials for MDMA for the treatment of PTSD; iboga and ayahausca are used in addiction treatment in other nations. And, of course, John Hopkins opened the first psychedelic research center last month.

But a center focused solely on magic mushrooms?

Thank Toronto-based FieldTrip Ventures for that. Ronan Levy is one of the founders. Having cut his teeth in the Canadian medical marijuana business, I was excited to chat with him about this exciting new project (you can hear our full conversation here). The sixties might have been the golden era of psychedelic experimentation, but we are entering a new phase of clinical research to discover just how effective they are for treating a range of mental health conditions. Given the results this far, a new era has begun.

Derek: On FieldTrip's website, it says the mission is "to heal the sick and better the well." Let's start with the healing.

Ronan: The evidence suggests that psychedelics, broadly speaking, can help treat a number of mental health conditions, ranging from depression to anxiety to OCD to addiction. There are studies now looking at anorexia and eating disorders as well. Not all of them have been conducted at clinical-trial levels, but there's definitely been trials on a small scale for all of those conditions. Psilocybin, in particular, has been studied for use in the treatment of depression as well as addiction. I think almost any mental health condition may benefit from psilocybin and other psychedelics. That seems to be where the evidence is leading.

Derek: Their illegality is especially frustrating considering the efficacy rates of SSRIs. What would you say to someone who is thinking about trying psychedelics but is still on other medication?

Ronan: We don't advocate that anybody attempt to undertake a psychedelic experience on their own. There is evidence to suggest that these molecules can be very effective in the context of psychedelic-assisted psychotherapy. It's not as well understood outside of that. The effects are unknown in terms of "Will it help?" Many people anecdotally say it absolutely does, but then there's broader concerns of whether you're not carefully considering what other medications or supplements you're using. We would say do it under the context of a medical professional, but presently there are no medical professionals licensed to actually provide psychedelic-assisted psychotherapy. At this point, we don't advocate that people try this out on their own until it's better understood.

Derek: Michael Pollan writes extensively about the need for a guide, someone leading you through the experience.

Ronan: That's where the evidence is and we'll follow the evidence. That certainly doesn't mean that it doesn't merit exploring the potential of psychedelics outside of the context of psychedelic-assisted psychotherapy. However, there's no evidence on that yet right now, so we remain neutral.

Photo by Richard Lautens/Toronto Star via Getty Images

On site are representatives Johnathan Werynski (left) and Ronan Levy from CanvasRX.

Derek: Understood. I appreciate your focus on being evidence-based. I'm also an advocate for cannabis. One thing that has perturbed me has been the CBD explosion, when the efficacy rate in all the studies that I've read is4 00 milligrams and above, yet coffee shops sell five milligrams for $8. Do you foresee any dangers of this happening with psychedelics?

Ronan: There is potential danger. They're powerful molecules. They're psychoactive and psychotropic. Anytime you're affecting brain chemistry merits caution and prudence. Do I foresee a future where they're being added to coffee? Not likely, no. Just like you're not going to see THC being added to coffee, at least in a legal context. There are risks that bad actors or people really interested in making a buck create products that aren't necessarily safe, which lead to bad outcomes, which may lead to political backlash. Right now it seems there's a lot of momentum in favor of psychedelics, and we want to keep that momentum. The best way to do that is to make sure to advance in a very thoughtful way.

Derek: You might be wrong on one of those counts. Here in Los Angeles, the first sanctioned cannabis cafe just opened.

Ronan: That's fair. I'm not familiar. It seems that the FDA's stated position is still that CBD is not permitted in any food product. I assume the same applies on the federal perspective on THC. Hopefully, whoever's opening that cafe is doing it really thoughtfully. No one needs a bad experience.

Derek: Speaking of cannabis, you started your work with Grassfed Ventures. Was cannabis your gateway drug into psychedelics?

Ronan: Even before Grassfed Ventures, four of the five founders of FieldTrip had started two sister companies, Canadian Cannabis Clinics and CanvasRX. Canadian Cannabis Clinics is the largest network of specialized medical clinics in Canada. That's where we got our experience with alternative medications or plant-based medications.

We're open-minded, but I'd say a little bit skeptical as to the therapeutic applications of cannabis when we first started. All of us were quite moved emotionally and quite convinced logically and intuitively that cannabis is a very effective medicine for a lot of people in the therapeutic applications. When we left to start the next thing, we became aware of psychedelics and saw the parallels between cannabis and psychedelics in terms of the evidence supporting therapeutic use, which is actually greater with psychedelics than there has been for cannabis. So yes, cannabis was our gateway into psychedelics.

Derek: You're opening the first psilocybin research center in Jamaica at the University of the West Indies, which I find fascinating and important. How did you choose that location? Can you talk about the function of the center?

Ronan: When we became aware of the opportunity around psychedelics in terms of its therapeutic value, we ran into the challenge that anybody looking at the space runs into, which is how to build a business in an illegal industry. We're not interested in doing anything illegal. As we did our homework, we realized that there are a few jurisdictions around the world in which psilocybin mushrooms are legal. Jamaica is one of those places. Through our work in the cannabis industry, we had great contacts down there. We had very constructive conversations and became aware that there's openness to it. It made sense to start with Jamaica.

So we are opening the world's first legal research and cultivation facility focused on psilocybin-producing mushrooms in conjunction with the University of the West Indies. We have the expressed support of various ministers and various levels of government to do this work. The focus of the research facility is to essentially do a lot of the work that's been done on cannabis over the last 10 years: focus on genetics, strain development, and understand the molecular chemistry of psilocybin mushrooms. We want to understand what other molecules are of interest, which may have therapeutic effects, and isolate them, as well as develop the standards for testing for all of these things. Really, doing anything you think may have been relevant to the development of the cannabis industry.

Derek: Why did you specifically choose mushrooms?

Ronan: The business rationale is that there's a lot of white space to be studied and lots of IP to be developed. From a societal perspective, the embrace of psilocybin-producing mushrooms is going to be much easier than with the more robust experiences that you have with DMT or ayahuasca. Our hope for the facility in Jamaica is that we will eventually expand into other plant-based psychedelics, but there's enough work to be done on psilocybin-producing mushrooms, all 200 or so genetic strains.

Photo by Fotoholica Press/LightRocket via Getty Images

Roger Lopez, Shaman of a Shipibo community in the Amazon jungle, conduct a session of Ayahuasca.

Derek: When you talk about IP and moving into pharmaceuticals, are there any dangers that you foresee anyone being disturbed by that sort of approach to what some people consider sacred medicine?

Ronan: It's something we're certainly conscious and aware of. I don't anticipate it being an issue. Our perspective is we have no interest in diminishing the heritage or sacred beliefs of any culture. But we do believe that a consciously-operated, for-profit entity is the best way to help make the therapeutic value of psychedelic molecules available to the greatest number of people. We're trying to find the appropriate balance between cultural sensitivity and good business practices.

Derek: I originally discovered mushrooms and other psychedelics in the early nineties. It was in an environment and a community that talked about Terence McKenna and the hero's dose. In the last few years, microdosing has become very popular. I was skeptical at first, but then came to the conclusion that dosage matters and whatever helps is important.

Ronan: It hasn't been studied in depth and therefore the effects, whether it's effective or not, is not well understood. More importantly, if people perceive they're being helped then they are being helped. Whether it's the pharmacology involved in the microdosing or just the placebo effect is of less importance in my mind. The bigger concern is that the effects of long-term use of psilocybin at microdosing levels isn't well understood, so there's potential health consequences around it. A couple of months ago, the first observational study on microdosing came out and it seems very promising, but I think more research needs to be done.

Derek: Have you envisioned any sort of rollout of training courses that would be developed as the research evolves?

Ronan: Absolutely. With clinical trials going on right now, by and large the protocols that they're using are very labor- and time-intensive on part of a psychotherapist. It makes sense because they want to achieve the greatest potential results. There's a lot of work that needs to be done in terms of optimizing delivery of these services and minimize the amount of psychotherapist time that needs to be involved to deliver as good if not better outcomes than currently prescribed by the protocols.

Training people is going to be essential as you scale this, but there's not a whole lot of evidence on what to base training on outside of what exists in the current clinical trials. You can see really effective training materials and courses coming out because there hasn't been a lot of experimentation in terms of how the psychotherapy is being delivered. There are protocols that are being used right now similar to the ones that were developed in the fifties and sixties, which haven't been studied in depth as to whether the amount of psychotherapy work involved is necessary.

--

Stay in touch with Derek on Twitter and Facebook.

From Your Site Articles

Related Articles Around the Web

Read the original post:
The world's first psilocybin research center is opening in Jamaica - Big Think

Posted in Molecular Medicine | Comments Off on The world’s first psilocybin research center is opening in Jamaica – Big Think

The Real Problem With Beef – The New York Times

Posted: October 2, 2019 at 4:52 am

The potentially unhealthful effects of eating red meat are so small that they may be of little clinical significance for many people.

This finding, just released in multiple articles in the Annals of Internal Medicine, is sure to be controversial. It should certainly not be interpreted as license to eat as much meat as you like. But the scope of the work is expansive, and it confirms prior work that the evidence against meat isnt nearly as solid as many seem to believe. (While I had no role in the new research, I co-wrote a commentary about it in the journal.)

Red meat has been vilified more than almost any other food, yet studies have shown that while moderation is important, meat can certainly be part of a healthy diet.

This doesnt mean that there arent other reasons to eat less meat. Some point out that the ways in which cattle are raised and consumed are unethical. Others argue that eating red meat is terrible for the environment.

Recently, meat substitutes have emerged as a possible solution, but the promise is much greater than the reality, at least so far.

Burger King and other fast-food chains are trying out Impossible Foods burgers as a vegan answer to beef. Lets dispense with the idea that this is healthier in any way. The Impossible Whopper has 630 calories (versus a traditional Whoppers 660). It also contains similar amounts of saturated fat and protein, and more sodium and carbohydrates. No one should think theyre improving their health by making the switch.

What about the environmental argument? Almost 30 percent of the worlds ice-free land is used to raise livestock. We grow a lot of crops to feed animals, and we cut down a lot of forests to do that. But beef, far more than pork or chicken, contributes to environmental harm, in part because it requires much more land. The greenhouse gas production per serving of chicken or pork is about 20 percent that of a serving of beef.

Cows also put out an enormous amount of methane, causing almost 10 percent of anthropogenic greenhouse gas emissions and contributing to climate change.

There has been a lot of hope that Beyond Meats pea protein or Impossible Burgers soy could serve as beef burger substitutes, reducing the need for cows. Thats unlikely to happen, according to Sarah Taber, a crop scientist and food system specialist. Ground beef is not the problem; steak is.

Theres no profit to be made in ground beef, she said. That all comes either from leftover parts once cattle have been slaughtered for more expensive cuts, or from dairy cattle that have outlived their usefulness. If everyone gave up hamburgers tomorrow, the same number of cows would still be raised and need to be fed.

In other words, to improve the environment by reducing the number of cows slaughtered, wed need to find a way to replace the many other cuts of beef Americans enjoy. No lab, and no company, is close to that.

To greatly reduce the reliance on cows, wed also need to wean ourselves from our high level of milk consumption. The increasing use of alternative milks, like oats or soy, could help, but the dairy industry still dominates.

(The dairy industrys claims about the health of its product are somewhat overblown. Milk isnt nearly as necessary for health as many believe.)

Some companies are researching ways to replace the more complex cuts of meat that drive the market. These companies arent replacing beef with substitutes; theyre trying to grow it in the lab using stem cells.

Tamar Haspel, who writes on food policy for The Washington Post, has said such advances are not likely soon. Nor is it clear that they would have an overall positive impact, unless we are sure that this meat can be made in a more energy-efficient way than we can raise cattle.

If meat substitutes wont help in the short run, other things still might. Some believe that raising cattle on pastures, from birth until slaughter, might sequester carbon in the soil better than having cows finish their growth on feed lots. Researchers at the University of Florida argue that it can also be profitable for farmers in warmer climates to do just that. It would require the cattle industry to make significant changes, as well as to relocate, and it seems unlikely theyd be willing to do that.

Grass-feeding cattle without grain is the norm in New Zealand, but almost no one in the United States does it, Dr. Taber said.

Its also worth pointing out that it would probably take longer to raise cows this way, giving them more time to emit methane.

Other new developments could help with that problem. Some have proposed farming insects to make animal feed. And feeding seaweed to cows, even in small amounts, can significantly reduce their methane burps.

One problem with seaweed is that the component that helps reduce methane emissions is classified as a carcinogen by the Environmental Protection Agency. Its present in small amounts in seaweed, though, and humans have been eating seaweed safely for a long time. A larger problem is that we are unprepared to farm the unbelievable amount of seaweed it would take to feed all the cattle the world is raising.

Picture a seaweed farm the size of Manhattan, Dr. Taber said.

Until people are truly ready to reduce consumption of dairy or consumption of higher-end beef cuts, or to commit to raising cattle differently, it seems unlikely that any of the changes with respect to ground beef will make a significant environmental difference in the near future.

That doesnt mean theres nothing we can do. I asked Dr. Taber what we might advise people, right now, to help the environment.

Who needs steak when theres bacon and fried chicken? she said.

Tiffany S. Doherty, Ph.D., Indiana University School of Medicine, contributed research.

Go here to read the rest:
The Real Problem With Beef - The New York Times

Posted in Florida Stem Cells | Comments Off on The Real Problem With Beef – The New York Times

VetStem Biopharma Shares the Success Story of Cheyenne Who Was Treated with VetStem Cell Therapy by Dr. Scott Reiners – PR Web

Posted: October 2, 2019 at 4:51 am

Cheyenne

POWAY, Calif. (PRWEB) October 01, 2019

Cheyenne is a beautiful and strong Quarter Horse and a huge part of her owners riding program. Mimi, Cheyennes owner, owns and operates Rebels Run, which offers riding lessons and trail riding in Afton, Virginia. According to Mimi, Cheyenne was a favorite amongst students and trail riding guests. Mimi describes her as her go to horse. Thus, you can imagine the devastation when Cheyenne tore her meniscus.

Mimi stated that Cheyenne was in a lot of pain and one of her veterinarians thought she may need to be euthanized. Fortunately, Mimi and Cheyenne were referred to Dr. Scott Reiners of Mountain View Equine Hospital to potentially receive stem cell therapy. Dr. Reiners is a board-certified veterinary surgeon and has been providing VetStem Cell Therapy since 2007.

Upon examination, Dr. Reiners diagnosed Cheyenne with Osteochondritis Dissecans (OCD) in addition to a torn meniscus and Degenerative Joint Disease (DJD) in her right hind knee. He recommended moving forward with stem cell therapy and began the process by collecting fat from Cheyennes tailhead in a minimally invasive surgical procedure. The fat was packaged and shipped overnight to the VetStem laboratory in Poway, California. Once received, VetStem laboratory technicians processed the fat to extract Cheyennes stem and regenerative cells to create injectable stem cell doses. Cheyennes stem cell injections were shipped to Dr. Reiners who received and injected them within 48 hours of the initial fat collection.

Due to the severity of the injury, Cheyenne required a second treatment with stem cells approximately 4 months after the first round of injections. Fortunately, VetStem had additional stem cell doses stored for Cheyenne so there was no need for a second fat collection procedure.

Mimi reported that the stem cell therapy was successful. She stated, After meeting with Dr. Reiners, I knew this would work. And boy did it! Cheyenne is 20 years old and fit as a fiddle. It brings tears to my eyes and joy to my heart to see her canter in every night for her feed. She is happy and pain free. Thank you so much VetStem for your part in her recovery!

Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a clinical case series using VetStem Regenerative Cell Therapy in horses with tendon and ligament and joint injuries, it was found that VetStem Regenerative Cell Therapy helped these horses to return to full work or to the activity level that the owner desired.

About Scott Reiners, DVM, DACVS, DACVSMRDr. Reiners received his DVM from Kansas State University and completed his surgical residency at Oklahoma State University. He and his wife, Dr. Wynne DiGrassie, started Mountain View Equine Hospital in 2003. Dr. Reiners special interests include orthopedic surgery, fracture/tendon repair, laser surgery, shockwave therapy, and sport horse lameness and rehabilitation.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Read more:
VetStem Biopharma Shares the Success Story of Cheyenne Who Was Treated with VetStem Cell Therapy by Dr. Scott Reiners - PR Web

Posted in Oklahoma Stem Cells | Comments Off on VetStem Biopharma Shares the Success Story of Cheyenne Who Was Treated with VetStem Cell Therapy by Dr. Scott Reiners – PR Web

Healing Chronic Pain and Inflammation With Plant-Based Foods – One Green Planet

Posted: October 2, 2019 at 4:51 am

Chronic pain is one of the most widely-recognized medical terms for the obvious reason that a majority of individuals suffer from some form of you guessed it chronic pain. This type of ailment differs from other types of pain as it usually negatively affects your daily life, making it difficult to accomplish normal tasks and it can eventually affect your mental health causing severe depression.

While chronic pain may stem from many different sources an injury, a disease or condition, or an unknown source one of the persistent and almost universal causes is chronic inflammation.

Youve most likely heard this term thrown about frequently in the health world lately. Inflammation is quickly becoming the leading cause of many health conditions outside of chronic pain including poor gut health, autoimmune diseases, mental health disorders, and even cancer.

When it comes to chronic pain, inflammation is generally pinned down as the underlying culprit.

The consequences of chronic inflammation in relation to chronic pain can be far-reaching including a build-up of scar tissue, decreased flexibility, hardening of arteries (which can lead to atherosclerosis), and even the acceleration of joint degeneration leading to arthritis. All of these factors may be causing a different type of pain that you would never associate with inflammation.

What can you do to help heal your body and reduce pain?

Try integrating plant-based foods into your diet! Recent studies have shown that a high intake of plant-based foods may be a leading intervention to help decrease the level of inflammation and help manage chronic pain. Plant-based foods are naturally rich in antioxidants and anti-inflammatory agents, as well as vitamins, minerals, and essential macronutrients.

nastya_gepp/Pixabay

Chronic pain also called chronic pain syndrome refers to pain which forgoes so-called normal types of pain, which occur after an injury heals or an illness runs its course. Chronic pain can draw out for months or even years, oftentimes without a specific known cause or trigger. If constant pain lasts longer than three to six months, your doctor will generally categorize it as chronic pain. Chronic pain syndrome is so prevalent in the states, that it is said to affect some 25 million Americans.

While pain is different for every person, chronic pain is generally experienced as joint pain, muscle aches, and burning pain. On top of that, chronic pain is also experienced in less obvious ways such as severe fatigue and sleep issues, mood problems depression, anxiety, irritability and even loss of stamina or flexibility, generally caused by a lack of activity due to the chronic pain.

qimono/Pixabay

Depending on the cause of chronic pain, there may be different things happening in your body. With that said, most chronic pain sufferers share a few things in common. First off, with chronic pain your body continues to send pain signals to your brain, even after an injury heals, meaning that the trauma or illness may have healed, but your body still believes its in pain. Secondly, most people suffering from chronic pain generally are also suffering from some sort of bodily inflammation, inflammation-related disorder, or chronic inflammatory issue.

Unfortunately, chronic pain can affect any part of your body. Yet, there are a few more common areas of issue including headaches, postsurgical pain, post-trauma pain, lower back pain, cancer pain, arthritis pain, neurogenic pain, caused by nerve damage and psychogenic pain unknown pain that is not caused by disease, injury, or nerve damage.

Ben_Kerckx/Pixabay

Causes of chronic pain vary depending on the person and their particular situation.

Possibly, its an injury that did not heal correctly or trauma from a surgical procedure. It could also be a lingering ghost pain from an illness that created a miscommunication between the brain and the nervous system, so that your body doesnt know its not in pain anymore. This type of ghost pain is continually worsened in a cycle as chronic pain changes the way neurons behave, making them hypersensitive to pain messages.

Basically, nerve cells are damaged by pain thereby making the pain worse.

With that said, there are a few common conditions that are known causes of chronic pain syndrome including back pain stemming from muscles strains, nerve compression, or arthritis of the spine osteoarthritis the wearing of the protective cartilage between bones fibromyalgia a neurological condition that causes pain and tenderness for unknown reasons advanced cancer in the body, and autoimmune diseases, in particular, rheumatoid arthritis inflammation of the joints and inflammatory bowel disease inflammation of the digestive tract.

Noupload/Pixabay

There may be a handful of conditions that cause chronic pain, yet one of the most common triggers and instigators of pain is bodily inflammation.

What is inflammation?

You may be familiar with this word as its become a hot button term in the health world over the last few decades. While inflammation has gotten a bad rap, its actually an essential and normal bodily response. For instance, when you are injured or get infected, your body signals the immune system to send white blood cells to the affected areas to repair the injury or fight the infection. Basically, an inflammatory response is meant to keep you safe and healthy.

Unfortunately, sometimes the inflammatory response can go a little haywire, when your immune system gets turned on and stays on after the crisis has passed whether its due to diet, disease, condition, or injury. This leads to chronic inflammation, which is a condition that can cause a slew of health issues including an increase in the risk of heart disease, diabetes, certain cancers, and even Alzheimers disease, as well asdamage [to] healthy cells and organs and [causing] constant pain in muscles, tissues, and joints.

Hence the connection between chronic pain syndrome and chronic inflammation.

rawpixel/Pixabay

So, chronic inflammation is a key component in chronic pain. How can you combat inflammation?

First off, talk to your doctor about this as a possible cause or component of your pain. There are certain tests that your doctor can perform to check your inflammatory health. They may also have a special course of treatment particular to your exact situation.

With that said, diet plays a huge role in both causing and mitigating inflammation.

Per Dr. Fred Tabung a visiting researcher with the Department of Nutrition at Harvard in a Harvard Medical School article entitledCan Diet Heal Chronic Pain?a lot of chronic pain is the result of chronic inflammation, and the evidence is quite strong that your diet can contribute to increased systemic inflammation But your diet is also one of the best ways to reduce it. When it comes to reducing bodily inflammation, you cant get any better than plant-based foods. Most plant-based foods are naturally rich in anti-inflammatory properties, as well as antioxidants, polyphenols, and a variety of vitamins and minerals that boost health and protect your body from harm. Dr. Tabung explains that your diet can help support your immune system by having it turn on and turn off at the appropriate times [while] a poor diet can alter your immune system, so it acts abnormally, and can contribute to persistent low-grade inflammation.

Free-Photos/Pixabay

Its not just Dr. Tabung promoting this idea of the diet-inflammation connection. In fact, there is a whole slew of studies that support this theory and, in particular, the theory of a plant-based diet decreasing inflammation and helping to mitigate the symptoms of chronic pain syndrome.

In a 2015 study published in Complementary Therapies in Medicine600 participants followed a vegan diet for three weeks which significantly reduced C-reactive protein, a key marker for acute and chronic inflammation. Another study in 2010, published inthe Journal of the American Dietetic Association, observed 79 rheumatoid arthritis patients who [performed] a vegetable fast for seven to 10 days, after which they were divided into two groups: one that followed by a vegan diet and another that followed a lacto-vegetarian diet a diet that includes dairy and eggs. While the lacto-vegetarians didnt see any change in pain, those that followed the vegan diet experienced significant improvement in tender and swollen joints, pain, duration of morning stiffness and grip strength.

Another study entitledChronic musculoskeletal pain and function improve with a plant-based diet published more recently in 2018 in Complementary Therapies in Medicinefollowed a small group of 20 participants in an eight-week diet intervention that focused primarily on plant-based foods in order to mitigate chronic musculoskeletal pain. While only 14 of the participants finished the study, the results found that the diet intervention resulted in decreased pain and improvement in quality of life.

ulleo/Pixabay

Want to start eating for your pain? Before changing your diet, make sure to consult your doctor! Every human body is different and your doctor can help you tailor a new diet to meet your specific bodily demands, sensitivities, allergies, and needs. After you get the thumbs up from your doctor, you can move forward with a new diet! Switching to a primarily plant-based diet is a great place to start and yet there are a handful of specific plant-based foods that target and reduce pain. Here are a few that have been found to be particularly effective when fighting pain symptoms.

Sugarless Grape Jelly/One Green Planet

Grapes are one of the best plant-based indulgences to have in your kitchen. This is especially true for those looking to cut out all refined sugar. Even though grapes are high in natural sugar one cup has around 23 grams they also happen to be a great source of vitamin A, vitamin K, choline, potassium, and they are rich in resveratrol, a powerful compound that blocks the enzymes that contribute to tissue degeneration. In recent studies, its been found that resveratrol may protect against the kind of cartilage damage that causes back pain.

Adding grapes into your diet is also super easy and enjoyable! They can be snacked on raw, directly after being washed or you can include them in meals such as this Cinnamon Spiced Apple and Grape Salad or even create your own DIY jellies such as this Sugarless Grape Jelly or this 3-Ingredient Grape Chia Jelly. Just remember to use red grapes if your aim is to reduce pain!

Ginger Tea/One Green Planet

If youre a health nut like me, you most likely already keep ginger in some form in your kitchen. This diverse and aromatic ingredient is not only great for naturally kicking nausea and easing digestion, but it also has been shown to help fight chronic pain symptoms. In a University of Miami-based study observing patients suffering from chronic knee pain, almost two-thirds of patients reported less soreness upon standing after taking a ginger extract.

It doesnt hurt that ginger also happens to be delicious! When youre consuming ginger for its medicinal properties, its best to get the most potent version. While extracts and powder varieties can be easy, nothing is better than consuming ginger in its raw form. When youre just starting out, try integrating raw ginger into other flavor-filled recipes such as this Sweet Potato, Ginger, and Coconut Soup, this potent Ginger Tea, or this Basil Pineapple Ginger Smoothie.

Raw Turmeric Ginger Smoothie/One Green Planet

For those that have been addressing inflammation for some time, turmeric is a staple in your kitchen. This traditional Indian spice contains a powerful anti-inflammatory agent called curcumin. Curcumin gives turmeric its rich yellowish color and is a powerful antioxidant that is known to help fight inflammation in the body. One study actually found that turmeric counteracted rheumatoid arthritis as effectively than ibuprofen! Consuming turmeric from the raw root is the most potent way to get the benefits of curcumin such as in this Raw Turmeric Ginger Smoothie (plus, youll also get the pain-fighting agents of ginger!). With that said, the powder form is more affordable and will last longer in your pantry. In order to boost the benefits of the powdered form, mix your turmeric spice with freshly ground black pepper such as in this Vegetable Pilaf Bowl with Creamy Turmeric Dressing.

Spicy Garlic Edamame/One Green Planet

Soy fights pain via isoflavones, which are plant hormones with anti-inflammatory properties. In a study conducted by Oklahoma State University, it was discovered that consuming 40 grams of soy protein daily for three months slashed [osteoarthritis] patients use of pain medication in half. Plus, soy is a great source of protein for plant-based eaters! If you want to integrate this pain-fighting agent into your diet, start out with classic edamame such as in this Spicy Garlic Edamame recipe or try your hand at some tofu-based meatless recipes such as this Tofu Steaks recipe or this Chicken Thai Red Curry With Fried Rice recipe.

Latte Macchiato/One Green Planet

To be honest, this one surprised me! When it comes to the pain-fighting powers of caffeine, there are a few different layers to the so-called coffee onion. First off, caffeine has been shown to enhance the effects of common painkillers such as aspirin and acetaminophen. Secondly, studies have also shown that caffeine has pain-lowering powers of its own at least when it comes to the pain associated with exercise. A University of Georgia-based study revealed that moderate doses of caffeine equivalent to two cups of joe reduced post-workout pain by almost 50 percent. Plus, caffeine can help boost your workout efficacy as well, which produces a higher level of endorphins making you feel better.

Want to spice up your coffee-intake routine? Try some creative coffee-based recipes such as this Cold Brew Ice Cream, Latte Macchiato, or this energizing Mocha Granola!

We also highly recommend downloading ourFood Monster App, which is available foriPhone, and can also be found onInstagramandFacebook. The app has more than 15,000 plant-based, allergy-friendly recipes, and subscribers gain access to new recipes every day. Check it out!

For more Vegan Food, Health, Recipe, Animal, and Life content published daily, dont forget to subscribe to theOne Green Planet Newsletter!

Being publicly-funded gives us a greater chance to continue providing you with high-quality content. Please support us!

Read more:
Healing Chronic Pain and Inflammation With Plant-Based Foods - One Green Planet

Posted in Oklahoma Stem Cells | Comments Off on Healing Chronic Pain and Inflammation With Plant-Based Foods – One Green Planet

CaverStem on the Big Island Giveaway! – EDGEOnTheNet

Posted: October 2, 2019 at 4:47 am

CaverStem is for men who want to live life to the fullest.

CaverStem is the only patented procedure using FDA-approved equipment performed by a licensed physician that provides a safe, effective, solution to treat erectile dysfunction using the patient's own stem cells to repair damaged tissue.

With this promotion, score a chance to win a free 4 night/5 day trip to Hawaii to have a CaverStem procedure performed by a licensed physician. Given the procedure only takes 30 minutes with no downtime, you will have plenty of time to take in the sun and fun!

Complete breakout of prizes below:

4 nights, 5 days all-inclusive trip to Honolulu, Hawaii (for two) and a CaverStem procedure performed by Dr. Scott Sanderson at Elite Health Hawaii.

Free CaverStem procedure at a Center of Excellence of your choosing and $1,000 to cover travel related expenses

Three additional winners will get 50% off procedure cards.

In order to enter the contest, please fill out the short form below.

Contest will run from Oct 1 - Dec 20, 2019 with winner being announced on Dec 21st.

CaverStem Featured On ABC News:

Fill out the following form to enter this contest. Starred (*) fields are required.

Click here for contest rules.* Please be aware that creating multiple accounts for the same person will disqualify you.

Read the original post:
CaverStem on the Big Island Giveaway! - EDGEOnTheNet

Posted in Hawaii Stem Cells | Comments Off on CaverStem on the Big Island Giveaway! – EDGEOnTheNet

Hoeven’s bill supports alternative therapy for veterans with PTSD, traumatic brain injury – Ripon Advance

Posted: October 1, 2019 at 11:49 am

U.S. Sen. John Hoeven (R-ND) on Sept. 18 introduced legislation to direct the U.S. Secretary of Veterans Affairs to furnish hyperbaric oxygen therapy to military veterans with traumatic brain injury (TBI) or post-traumatic stress disorder (PTSD).

Sen. Hoeven sponsored the TBI and PTSD Treatment Act, S. 2504, with bill cosponsor U.S. Sen. Kevin Cramer (R-ND) to provide veterans with hyperbaric oxygen therapy (HBOT), which involves breathing pure oxygen in a pressurized room or tube, according to the Mayo Clinic.

Our veterans deserve access to the best possible health care, and that includes alternative options like HBOT when traditional therapies arent delivering the outcomes our veterans need, Sen. Hoeven said.

HBOT is a well-established treatment for several conditions, the Mayo Clinic says, which noted that in a hyperbaric oxygen therapy chamber, the air pressure is increased to three times higher than normal air pressure so that a persons lungs can gather more oxygen, helping to fight bacteria and stimulate the release of substances called growth factors and stem cells, which promote healing.

The legislation would build on the VAs clinical demonstration program for HBOT, which earlier this month was expanded to the Fargo VA Health Care System in Sen. Hoevens home state. The local VA is the fifth location to be added to the HBOT program, joining VA systems in California, Florida, Oklahoma and Texas.

We worked for more than a year to bring HBOT access to veterans in North Dakota and Minnesota under the VAs clinical demonstration program, said Sen. Hoeven. With that program now under way, we are continuing to move the ball forward by advancing this legislation.

The bill has been referred to the U.S. Senate Veterans Affairs Committee for consideration.

Read more here:
Hoeven's bill supports alternative therapy for veterans with PTSD, traumatic brain injury - Ripon Advance

Posted in Minnesota Stem Cells | Comments Off on Hoeven’s bill supports alternative therapy for veterans with PTSD, traumatic brain injury – Ripon Advance

Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. – GlobeNewswire

Posted: October 1, 2019 at 11:47 am

Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity.

Amsterdam, The Netherlands 1st October 2019

Esperite N.V. (the Group) confirmed on 22nd February 2019 the intentions of the Group to sell its Cord Blood Stem Cells activities in an transaction composed by two main elements. The Storage Agreement signed between CryoSave AG and its new Polish partner, which main advantages is to consolidate all the samples from different country in one secured location and to secure a long term contract with a reputable company. The second element, related to the transfer of the main assets, as brand names, CryoSave and Salveo mainly, databases, websites and other IT tools, has been concluded finally on August 20th 2019 with the Myrisoph Capital Group (Myrisoph).The transportation of the samples from the different locations was completed and communicated with the press release issued on July 1st 2019. Anticipating the conclusion of the agreement formalized with a binding offer by Myrisoph, CryoSave took the decision to progressively terminate its activities in Switzerland. The laboratory in Plan-les-Ouates was shut down at the end of June 2019. After the Cord Blood Stem Cells samples have been safely transferred and the activity licenced to Myrisoph Capital, Esperite had no other choice than to accept the liquidation of its entities related to Stem Cell, CryoSave AG which deadline to oppose was on 26th September 2019. The Group will soon update the market on the impact on the consolidated revenues.Esperite has the intention take distance from the operative part of its activities and focus its effort on turning itself in an investment company with a focus on Health Care and High Tech Service.

ESPERITE group, listed at Euronext Amsterdam and Paris. To learn more about the ESPERITE Group, or to book an interview: info@esperitegroup.com or visit the websites at http://www.esperite.com.

See the original post:
Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. - GlobeNewswire

Posted in Stem Cells | Comments Off on Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. – GlobeNewswire

Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl – The Sun

Posted: October 1, 2019 at 11:47 am

MICHAEL Schumacher's doctor has warned fans that he "does not work miracles" following stem cell therapy he performed on the F1 star.

Dr Philippe Menasch has also slammed claims he was carrying out "experiments" on the legendary racing driver when he treated him in Paris last month.

4

4

Little was known about the stem-cell operation, but seven-time world champion Schumacher is believed to have received transfusions of inflammation-reducing stem cells.

Amongst the media flurry surrounding the top-secret op, local media reported on it as "experimental."

Menasche - known as a pioneer in stem-cell research - has slammed these claims, telling Italian newspaper La Republica: "I do not perform miracles.

"My team and I are not doing an experiment, an abominable term that is not in line with a serious medical view."

Schumacher's condition is not public knowledge, but after the procedure last month, a nurse toldLe Parisien: "Yes he is in my service ... And I can assure you that he is conscious."

The French paper also said Schumacher has been treated at least twice previously at the Georges-Pompidou hospital in Paris, admitted each time under a false name and treated by a small medical team.

It was also reported that the F1 driver was accompanied by security staff.

Schumacher's health has been shrouded in secrecy ever since a near-fatal brain injury he suffered in 2013.

The seven time F1 championsuffered severe head injuries on a family skiing holiday in the French Alps and has not been seen in public since.

What is stem cell therapy and how does it work?

STEM cell therapy is one of the most promising new medical treatments.

Stem cells are the body's raw materials - the cells from which all cells in the body are generated.

In the lab, scientists can take stem cells and help them divide to create daughter cells.

These daughter cells can either become new stem cells or turn into specialised cells - blood, brain, heart muscle, bone cells for example.

Scientists and doctors across the world hope stem cells could prove the breakthrough for treating a range of conditions, from heart disease to cancer.

How does it work?

One of the key ways stem cell treatment can work is to repair or regenerate damaged and diseased tissues.

By taking the cells and creating specialised heart muscle cells for example, doctors can help repair damaged heart muscle and use them to treat heart failure.

Who can benefit?

According to the Mayo Clinic in the US, patients with a wide range of illnesses and disease could benefit from the treatment.

They include those suffering:

Stem cells can also be used to grow new tissue that can then be used for transplants and regenerative medicine.

It means in future, stem cells could be used to grow new organs rather than relying on organ donation.

He was skiing with his son Mick when he fell and cracked his head on a boulder on the Combe de Saulire above Mribel.

The devastating injury left him paralysed and unable to speak.

Schumacher spent three months in a medically-induced coma after the accident and has had years of intensive care at his house in Gland, a Swiss town on the shore of Lake Geneva.

His condition now appears to have stabilised and in January this year he was taken by helicopter to the family's holiday home in Mallorca for his 50th birthday.

In a celebratory post on Instagram, his family wrote: "Please understand if we are following Michael's wishes and keeping such a sensitive subject as health, as it has always been, in privacy."

They confirmed that Schumacher was in "the very best of hands."

The wall of secrecy is reportedly enforced by his wife, Corinna.

Forumla One's head of motorsport, Ross Brawn has spoken publicly about Corinna's decision to keep her husband's health private.

He said: "I am constantly in touch with Corinna, and I totally agree with their decision."

Latest

STAR KILLED Grammy-award winning artist Louie Rankin dies in horror car crash

SPOT THE SPOTS Can YOU spot the leopard hiding in a ditch in this amazing viral pic?

STABBED IN CLASS Finland 'sword rampage leaves 1 dead & 9 injured as student storms school'

SAVAGE ATTACK Woman raped female victim with gun and poured acid on her' in row over 150

'MONSTER MUM' Mother mowed down & killed daughter & another woman during birthday party'

KILLED IN SLEEP Girl, 14, 'killed by exploding phone' after going to bed listening to music

"Michael has always been a very private person and that's been a guiding principle in his career, his life and his family always agreed with that choice.

"It's completely understandable that Corinna has wanted to maintain the same approach, even after the tragic event, and it's a decision we must all respect.

"I'm sure the millions of people who are still Michael fans will understand it, too."

4

4

We pay for your stories! Do you have a story for The Sun Online news team? Email us attips@the-sun.co.uk or call 0207 782 4368 . You can WhatsApp us on 07810 791 502. We pay for videos too. Click here to upload yours.

See more here:
Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl - The Sun

Posted in Stem Cells | Comments Off on Michael Schumachers surgeon denies hes performing experiments on F1 legend with stem cell treatment and sl – The Sun

Page 1,334«..1020..1,3331,3341,3351,336..1,3401,350..»